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BALANCING THE BARRIERS: EXPLOITING AND
CREATING INCENTIVES TO PROMOTE
DEVELOPMENT OF NEW TUBERCULOSIS
TREATMENTS
Patricia C. Kuszler*
Tuberculosis is one of the great medical paradoxes of our age. There are
powerful drugs to cure the disease, yet it is far from being eradicated.
Instead, it has re-emerged with the deadly form-the multidrug-resistant
tuberculosis . .. and it is gaining the upper hand unless other new
effective drugs are discovered soon .... 1
I. INTRODUCTION: TUBERCULOSIS AS A GLOBAL PROBLEM
As we face the tuberculosis epidemic of the twenty-first century, we
have before us a very different war than that which confronted our
forefathers of the nineteenth and early twentieth centuries.' Not only is
the tuberculosis bacilli endemic, infecting a third of the world's
population,3 but it has developed the capacity to resist our badly
antiquated antibiotic weapons.4 Tuberculosis (TB) is now the leading
cause of death from a single disease, accounting for over a quarter of the
* Assistant Professor, University of Washington School of Law. B.A., 1974, Mills College;
M.D., 1978, Mayo Medical School; J.D., 1991, Yale Law School.
1. K K Tan, Tuberculosis-Fighting a Losing Battle?, 36 Sing. Med. J. 209,211 (1995).
2. Tuberculosis was the leading cause of death in 19th century America, killing one in five
persons. Sheila M. Rothman, Living in the Shadow of Death-Tuberculosis and the Social
Experience of Illness in American History 2 (1994). Although other plagues such as the bubonic
"Black" plague and the 1918 flu epidemic have produced similar devastation, they lasted only a
short period of time and then were eradicated or burned themselves out. Laurie Garrett, The Coming
Plague-Newly Emerging Diseases in a World out of Balance 157-58, 23 8-39 (1994) Unlike these
plagues, tuberculosis has remained an ongoing public health threat for several centuries. Id. at 240-
41.
3. See Charles Marwick, Do Worldwide Outbreaks Mean Tuberculosis Again Becomes 'Captain
of All These Men of Death'?, 267 JAMA 1174 (1992); Phyllida Brown, A Disease that is alive and
kicking; tuberculosis returns to industrialized nations, World Health, July 1993, at 4.
4. See Alan B. Bloch et al., Nationwide Survey of Drug-Resistant Tuberculosis in the United
States, 271 JAMA 665 (1994); Thomas R. Frieden et al., The Emergence of Drug-Resistant
Tuberculosis in New York City, 328 New Eng. J. Med. 521, 524 (1993); Kent A. Sepkowitz et al.,
Trends in the Susceptibility of Tuberculosis in New York City, 1987-1991, 18 Clinical Infectious
Diseases 755 (1994).
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world's avoidable deaths.5 Recent estimates predict nine.y million new
TB cases by the end of this decade. 6 In dealing with the modem "white
plague,"7 we no longer have the luxury of dealing with the epidemic on a
community-by-community or nation-by-nation basis. We live in a global
village, linked to other nations and cultures by an ever increasing
mobility that renders us all increasingly susceptible to tuberculosis.'
Further complicating the epidemic is the increasing number of
tuberculosis cases resistant to one, two, or all of the existing anti-
tuberculosis drugs.9 This difficult-to-treat "multidrug resistant" disease
(MDR-TB) ensures the global spread of tuberculosis in ever more
5. Every year there are eight million new cases of tuberculosis and three million deaths caused by
tuberculosis. The disease accounts for 6.7% of all deaths in the developing world, 18.5% of all
deaths in adults aged 15 to 59 years, and 26% of avoidable adult deaths. JoLn Porter et al., The
challenge is international, World Health, July 1993, at 10. Currently TB kills more people
worldwide than any other infection, including AIDS and malaria. See Brown, supra note 3. It is
estimated that TB will claim 30 million lives during the coming decade; ove" 95% of these will
occur in the developing world, but industrialized nations will also experience dramatic increases in
TB disease and death. Dale I. Morse, Directly Observed Therapy for Tuberculosis: Spend Now or
Pay Later, 312 Brit. Med. J. 719, 719-20 (1996); Hiroshi Nakajima, Tuberculosis: A Global
Emergency, World Health, July 1993, at 3.
6. Mario C. Raviglione et al., Global Epidemiology of Tuberculosis: Morbidity and Mortality ofa
Worldwide Epidemic, 273 JAMA 220, 220 (1994).
7. The term "white plague" refers to the pallor of the patient afflicted with tuberculosis. The term
was popularized by Rene and Jean Dubos, in their history of tuberculosis in the 19th and early 20th
centuries. See Rene & Jean Dubos, The White Flague-Tuberculosis, Man and Society (1952). For
other renditions of TB's historical impact, see Barbara Bates, Bargainingfor Life-A Social History
of Tuberculosis, 1876-1938 (1992); Rothman, supra note 2; and F.B. Sm th, The Retreat of
Tuberculosis 1950-1950 (1988).
8. Joan Stephenson, Health at Home Means Watching the Global Village, 273 JAMA 1648
(1995). In 1993, the World Health Organization (WHO) declared TB to be a global health
emergency, a designation that had never before been applied to any single disease. Tuberculosis is
now considered the greatest single threat to the world's public health. See id. Lee B. Reichman,
How To Ensure the Continued Resurgence ofTuberculosis, 347 Lancet 175 (1996).
9. The development of drug resistance is due to inadequate or incomplete treatment of the
traditional strain of tuberculosis. Although public health clinicians in the mid-20th century had at
their disposal sanitaria and enforceable public health laws, both of these diminished in the latter part
of the century. As a result, adherence to treatment plans eroded. Patients became less likely to
complete their treatment regimens. In addition, physicians became less familiar mith tuberculosis and
its pathogenesis as the disease decreased in inzidence; thus the medical profession became less
effective at administering adequate therapy. Michael D. Iseman, Evolution of Drug-Resistant
Tuberculosis: A Tale ofTwo Species, 91 Proc. Nat'l Acad. Sci. U.S. 2428 (1994). "We have turned a
disease that was completely preventable and curable into one that is neither." D; Lee B. Reichman,
President, Am. Lung Ass'n, quoted in Michael Specter, Neglectedfor Years, TB .rs Back with Strains
That Are Deadlier, N.Y. Times, Oct. 11, 1992, at Al. This phenomenon is no: unique to TB, but
applies to virtually all infectious diseases. Microbes are vested with high intrinsic mutability and
rapid replication. As such, they present a constantly-evolving adversary. See Joshua Lederberg,
Infectious Diseases-a Threat to Global Health and Security, 476 JAMA 417 (1996).
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dangerous forms.' ° Unlike the TB of old, this virulent MDR-TB can
result in quick death, especially if the patient's immune response is
compromised by age, concurrent human immunodeficiency virus (HIV),
or other chronic illness."' TB is already out of control in most of the
world, and has become a substantial threat even in nations previously
regarded as "safe."' 2 In order to reverse this epidemic, the dense social,
economic, and cultural barriers preventing effective prevention and
treatment must be alleviated or circumvented." This will be virtually
impossible unless new, more effective treatments are discovered.
This Article considers the many barriers that health-care providers and
public health authorities face in stemming the modem TB epidemic. Part
II reviews historical public health measures, their results, and their
adaptability to resurgent and MDR-TB. Part III considers the
fundamental barriers to a successful global effort using these public
health strategies, concluding that these barriers are insurmountable given
the current arsenal of anti-tuberculosis therapies. Part IV examines the
reasons why research and development of new anti-tuberculosis drugs
and vaccines have stagnated over the last quarter century. Finally, part V
explores incentives that might revive research and development of such
therapies and thus tip the scales toward control of this dangerous new
white plague.
10. In the 1960s and 1970s, only one to two percent of tuberculosis strains evidenced resistance to
existing drugs, and the resistance was limited to only one of the available drugs. The propensity for
drug resistance has risen steadily. In 1992, 33% of tuberculosis strains found in New York City
patients were resistant to at least one drug; 19% were resistant to two or more drugs. In developing
nations, drug resistant strains are present in over 30% of cases. Iseman, supra note 9, at 2428. Others
report even higher incidences of drug resistance. See Marwick, supra note 3. By 1991-92, one strain
of tuberculosis (the "W-strain"), appearing initially in New York City, had developed resistance to
every available drug and had a 50% mortality rate. Laurie Garrett, The Return ofInfectious Disease,
Foreign Aff., Jan.-Feb. 1996, at 66.
11. For example, HIV patients are extremely susceptible and vulnerable to MDR forms of
tuberculosis: "[I]n fact, the HIV-positive are 40 times more likely to contract and develop
tuberculosis that those who are HIV negative." Rosemary G. Reilly, Combating the Tuberculosis
Epidemic: The Legality of Coercive Measures, 27 Colum. J.L. & Soc. Probs. 101, 104 (1993).
12. See Nakajima, supra note 5. Asia illustrates the tuberculosis epidemic at its worst; notably,
HIV is also prevalent in developing Asian nations. It is estimated that nearly half the Asian
population is infected with TB. The death rate for patients dually infected with TB and HIV is
doubling every three to five years. See U.S. Dep't of Health & Human Servs., Tuberculosis, HIV Co-
epidemic to Multiply Sevenfold in Asia, Pub. Health Rep., Jan.-Feb. 1995, at 108.
13. The tuberculosis epidemic, like most other infectious disease epidemics, is rooted in
"conditions of social despair inflicted by one class of human beings upon another." Garrett, supra
note 2, at 214 (citing Dubos & Dubos, supra note 7).
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II. TUBERCULOSIS AND TRADITIONAL PUBLIC HEALTH
STRATEGIES: TRIED, BUT NO LONGER TRUE
Tuberculosis is an ancient disease, dating back to the dawn of
humanity. Evidence suggests that TB was present in ancient Babylonia,
Egypt, and Greece. 4 For most of TB's long history, its cause was
mysterious and elusive. Ancient Egyptians believed tuberculosis was
rooted in the supernatural. Later, in the fifth century B.C., the Greek
physician Hippocrates meticulously chronicled the signs and symptoms
of tuberculosis, naming it phthisis, meaning to melt and waste away."
Well into the nineteenth century, some healers believed tuberculosis to
be a hereditary weakness; others believed, more accurately, that phthisis
was contagious and transmitted through the air. The ancient Greeks were
prescient; an isolation treatment philosophy prevailed well into the
twentieth century. Early physicians also employed various methods of
"bleeding" and administered a variety of caustic medications, both orally
and directly into the chest cavity, to treat phthisis."6
By the mid-nineteenth century, phthisis had acquired the Anglicized
name consumption. Modem scientific inquiry had revealed that phthisis
resulted from pathologic tubercle lesions found in the bones and tissues
of patients with consumption.' Nevertheless, most cultures continued to
view consumption as an immutable fact of life, a back-handed act of
God, visited upon rich and poor alike, and largely resilient to any human
intervention.'" "Tuberculosis was. inscrutable as Providence."' 9 This
attitude began to lose credibility in 1882, when Robert Koch, a German
14. For example, the bones of 3000-year-old Egyptian mummies show signs of tuberculosis;
similarly, bony deformities associated with TB are represented in statuary dating back to 4000 B.C.
Dubos & Dubos, supra note 7, at 5.
15. J. Arthur Myers, Captain ofAll These Men of Death-Tuberculosis Historical Highlights 11
(1977).
16. See id. at 12-17. Hippocrates and the physicians that followed him believed that good
nutrition and exposure to healthful air were critical to prevention and treatment of the disease; as a
result climatic changes and relocation to the mountains or seaside were recommended.
17. Id. at 34. These tubercle lesions are the result of the baccilli's destruction of normal lung
tissue and replacement with small collections of necrotic matter. See I Kurt J. Isselbacher et al.,
Harrison's Principles of Internal Medicine 711-12 (13th ed. 1994).
18. Dubos & Dubos, supra note 7, at 210.
19. Smith, supra note 7, at 1. Nevertheless, as Smith documents, "Tuberculosis respected rank."
Although the rich were as vulnerable to tuberculosis exposure as the poor, thoe with financial and
social resources fared better in escaping active infection and in availing themselves of earlier access
to treatment Id. at 10.
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bacteriologist, discovered the microscopic bacillus responsible for the
tubercles and the disease.20
Once Mycobacterium tuberculosis2' had been defined as the cause of
tuberculosis, the contagious nature of the disease received more
dedicated attention. Indeed, the discovery of the microbiologic etiology
of tuberculosis and other contagious diseases produced a pronounced
shift in public health policy. Prior to these scientific discoveries, public
health efforts had targeted public hygiene, attempting to improve general
living conditions and provide safe food and water supplies.' These
efforts were not in vain; in the decades prior to the discovery of
Mycobacterium tuberculosis, the mortality rate from tuberculosis
markedly declined.' With the discovery of a microbiologic etiology for
tuberculosis and other common infectious diseases, public health efforts
began to focus on protecting individuals from the hazards of their
environment, rather than changing the environment.24 In the case of
tuberculosis, now known to be caused by an airborne bacilli passed from
the infected to the non-infected, this translated to increased momentum
for public health detection, isolation, and mandatory treatment of
infected patients.
20. Dubos & Dubos, supra note 7, at 101,210.
21. Tuberculosis results from chronic infections with Mycobacterium tuberculosis; the bacteria
infects tissues of the lung, bone, and other organs, resulting in the formation of granulomas-areas
of inflammation and decay. See Isselbacher et al., supra note 17, at 711-12. Mycobacterium
tuberculosis is one of more than 30 members of the genus Mycobacterium. Other member of the
genus also infect humans, notably, Mycobacterium leprae, the microbe responsible for leprosy. See
id at 710.
22. The public health efforts to improve living conditions were tremendously successful.
Numerous infectious diseases, including cholera and typhoid, lost their status as mass killers as a
result of improved sanitation and public health education. See generally John Duffy, The
Sanitarians: A History ofAmerican Public Health (1990); John Duffy, A History of Public Health in
New York City (1968); Garrett, supra note 2.
23. By 1900, the mortality rate from tuberculosis had dropped to half of what it had been in the
middle of the 19th century, both in Europe and in the United States. Dubos & Dubos, supra note 7,
at 186; Smith, supra note 7, at 236-37. How much of this decline was due to improved living
conditions and how much was due to the periodic waning that is characteristic of infectious diseases
is unknown.
24. Sylvia N. Tesh, Miasma and "Social Factors" in Disease Causality: Lessons From the
Nineteenth Century, 20 J. Health Pol. Pol'y & L. 1001, 1004 (1995). Tesh notes that a second factor
fueling the change in public health strategy was the political ideology of the time. The public health
concentration upon sanitary reform and improved living conditions went hand-in-hand with the
economic liberalism of the time. As this political theory lost vitality, the public support for the
sanitation effort waned, and support for more aggressive public health actions in the form of
quarantines and other coerced treatments gained strength. Id. at 1005.
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A. The Old Tuberculosis: A Historical Overview of Public Health
Measures
After the discovery of the tuberculosis microbe and the growing
consensus that consumption was an infectious disease, New York City
took the lead in devising a public health approach to the disease.' In
1889, the New York City Commissioner of Health commissioned a
summary report on the contagiousness of tuberculosi:3. One of the
physicians preparing this report, Dr. Herman Biggs, went on to submit a
plan to control tuberculosis in the city. The plan called for the following:
a systematic public education campaign to inform citizens of tuberculosis
risks and preventive measures; compulsory reporting of all tuberculosis
cases; new laboratories to aid in rapid and efficient diagnosis of patients;
public health inspectors dedicated to monitoring the homes and treatment
of patients known to have tuberculosis; establishment of special isolation
wards in hospitals; and a new specialty hospital dedicated solely to care
of tuberculosis patients.26 Dr. Biggs's public health strategy, originally
conceived in 1893, did not enjoy easy acceptance;27 it was not until 1907
that the plan was fully implemented by New York City.2" Nevertheless, it
would become the model for public health authorities throughout the
United States as they attempted to control tuberculosis. 9
Most states passed laws to codify the public health strategy to be
applied to tuberculosis3 The typical state law provided for mandatory
screening of certain populations, frequently schoolchildren or persons
25. Myers, supra note 15, at 59; Barron H. Lerner, New York City's Tuberculosis Control Efforts:
The Historical Limitations on the "War on Consumption, " 83 Am. J. Pub. Health 758, 758-59
(1993).
26. Lerner, supra note 25, at 758-59.
27. In fact, the medical profession bitterly opposed the Biggs plan and 3ought to enjoin its
implementation by proposing a series of bills to the State Legislature that would strip the Board of
Health of any authority in dealing with tuberculosis as an infectious disease. Myers, supra note 15, at
59. The basis for their opposition was manifold: some adhered to the "anticontigionist" philosophy
which held that genetically predisposed individuals contracted tuberculosis by exposure to harmful
"miasmas"; others alleged that the mandatory reporting required them to breach a patient confidence.
Lerner, supra note 25, at 758-59.
28. Myers, supra note 15, at 59.
29. Dubos & Dubos, supra note 7, at 211. Nearly 40 states have laws addressing control of
tuberculosis, most of which were drafted around the turn of the century and are similar to the New
York City model. See Lawrence 0. Gostin, Conrolling the Resurgent Tuberculosis Epidemic: A 50-
State Survey of TB Statutes and Proposals for Reform, 269 JAMA 255 (1993); Karen H. Rothenberg
& Elizabeth C. Lovoy, Something Old, Something New: The Challenge of Tuterculosis Control in
the Age ofAIDS, 42 Buff. L. Rev. 715, 743 (1994).
30. Gostin, supra note 29, at 255.
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working in the food or health-care industries. Other provisions required
testing of persons suspected to be harboring infectious tuberculosis;
positive results were reported to the state or local authorities; this then
triggered enhanced public health education efforts and monitoring."
When an individual was found to have active TB, and was recalcitrant or
otherwise deemed an infectious danger to others, he or she could be
confined to a TB treatment facility under the color of state law.32
1. Isolation and Supportive Care as Treatment
The increased isolation and institutionalization of tuberculosis patients
dovetailed neatly with the sanitarium movement popular in Europe at the
turn of the century.33 Perhaps as a result of societal acceptance,
institutionalization frequently was accomplished without resorting to
state police power, through voluntary enrollment by the patients. The
campaign to prevent and cure tuberculosis enjoyed wide public support.34
Many patients eagerly sought care in a tuberculosis sanitarium, even if
the institution was a public one; in fact, demand soon outpaced supply.
Unfortunately, sanitarium treatment produced few miracles. Many
patients, arriving too sick to derive significant benefit from the care,
became permanent residents. Others stayed long enough to regain their
strength, but, pressed to return to their family responsibilities, left while
still contagious with TB. 35  As an unfortunate aside, while the
tuberculosis campaign focused on the sanitarium model of treatment,
31. See Kathryn Render, Tuberculosis Chapters: A Model for Future AIDS Legislation?, 32 St.
Louis U. L.J. 1145, 1149-56 (1988). For a state-by-state breakdown of specific provisions applicable
to public health powers, see Gostin, supra note 29, at 256-57.
32. See Render, supra note 31, at 1157. A recent survey of state laws revealed that 19 states
provide for emergency detention for reasons of health. Nine of these vest the authority for such
detention solely in the discretion of a health officer, eight require a court order, and four provide for
detention in the context ofcommitment. The criteria for detention range from failure to comply with
counseling suggestions to being deemed a public health threat. See Gostin, supra note 29, at 258.
33. The European model of treatment was based on the theory that stress and complicated urban
life impeded recovery from tuberculosis. In this model, patients were institutionalized in healthcare
facilities and given the opportunity to rest, receive a nutritious diet, and breathe healthy, preferably
cold, mountain or sea air. Sanitaria flourished throughout Europe; in the United States, the premier
sanitarium was at Saranac Lake in the Adirondacks. See Dubos & Dubos, supra note 7, at 176-78.
34. This support coincided with a shift in the perception of who would be the caretaker of the
sick. Whereas in the previous century, the caretakers were the family and friends of the patient, the
twentieth century saw this role increasingly assumed by physicians, nurses, clergy, and other care-
taking professions. Bates, supra note 7, at 329.
35. Id. at331.
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public health energies were deflected from social reform, public
sanitation, and improvement of living conditions.36
Tuberculosis was fostered by substandard, crowded living conditions
in which the tuberculosis patient lived until he or she gained entry to a
sanitarium or succumbed.37 Once institutionalized, the patient either
became a chronic care resident of the sanitarium or recovered enough to
return home, potentially infect others, and/or become reinfected with
tuberculosis. The system and infrastructure that had been created to
prevent and cure tuberculosis evolved into a long-term care system that
did neither.3" The battle against tuberculosis had evolved into a standoff.
2. Science Searches for an Effective Cure
Science continued to delve into a variety of treatments for
tuberculosis. Much research focused on the search for a vaccine, such as
those that had been developed for smallpox and anfhrax.39 Almost
immediately, it became evident that tuberculosis was a far more complex
pathogen. Numerous vaccines were attempted with litule success. In
1926, the most promising of them, the Bacillus Calmette Guerin (BCG),
was mistakenly implicated in a research tragedy that claimed the lives of
seventy-six hospitalized infants in Lubeck, Germany."' The incident
provoked great fear and chilled tuberculosis vaccine research.4'
In 1943, Dr. Selman Waksman isolated a drug from a stain of bacteria;
it proved to be effective in reversing and curing even -.evere cases of
tuberculosis. By 1947, this drug, streptomycin, became the primary
"first-line" treatment for tuberculosis patients.42 In 1948, para-amino-
salicylic acid, another anti-tuberculosis drug, became available. This was
36. Lerner, supra note 25, at 760.
37. Poor sanitation and crowded living conditions provided an ideal environment for the spread of
tuberculosis. See Dubos & Dubos, supra note 7, at 202.
38. See Bates, supra note 7, at 329-3 1.
39. See Myers, supra note 15, at 36-37.
40. Instead of the non-virulent BCG vaccine, the infants were vaccinated with live human
tuberculosis bacilli. See Dubos & Dubos, supra note 7, at 122-23, 160-62.
41. See id. at 162. BCG later was found to be somewhat effective in immunizing against
tuberculosis. However, the immunizing effects of BCG are extremely variable and inconsistent; its
efficacy as a vaccine remains inconclusive to this day. See infra part IV and accompanying notes.
42. Dr. Waksman faced innumerable difficulties in getting the new drug tested and used as
treatment. He was not a medical doctor, but a soil bacteriologist; this hindered the acceptance of his
research, even though the results were dramatic. As a result the drug was not d stributed until 1947.
Smith, supra note 7, at 246.
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followed by a third drug, isoniazid, in 1952. 4' Several other drugs
followed, with the last major anti-tuberculosis drug, rifampin, being
introduced in 1972.' 4
The advent of effective antibiotics revolutionized care of patients with
tuberculosis. Finally, patients who required hospitalization were likely to
return home with cured or quiescent, noninfectious tuberculosis." More
important, the vast majority of patients could be treated effectively on an
outpatient basis, never requiring hospitalization.46 The death rates from
tuberculosis plummeted; for example, in England and Wales, mortality
among young women fell by ninety-nine percent from 1951 to 1961.4"
By the mid-1950s, the massive institutional infrastructure that had
provided care to tuberculosis patients began to dissolve; tuberculosis
wards and sanitaria closed or were rededicated to other uses.4" By the
1970s, dedicated TB facilities and units were virtually nonexistent.49
The dramatic success of the new anti-tuberculosis drugs sparked
tremendous optimism, giving rise to the widespread delusion that
tuberculosis would soon be eradicated."0 As mortality rates continued to
decline, efforts to control tuberculosis became less rigorous. Funding for
large scale tuberculosis education projects and public health monitoring
shifted to other acute medical and societal problems.5' Private
philanthropic organizations founded to aid in the prevention and cure of
tuberculosis broadened their mission to include all respiratory diseases.52
43. Id.
44. Rifampin is the second most important anti-tuberculosis drug, after isoniazid. As in the case of
isoniazid, liver dysfunction is a adverse side effect. See Isselbacher et al., supra note 17, at 706. It is
substantially more expensive than isoniazid.
45. Lemer, supra note 25, at 760.
46. Smith, supra note 7, at 247.
47. Id.
48. Bates, supra note 7, at 339-40.
49. See, e.g., Lerner, supra note 25, at 761 (discussing situation in New York City).
50. This optimism was not confined to tuberculosis. The post-World War II world believed that
the antibiotics, antimalarials, and vaccines that had been developed had indeed effected a "health
transition" and that infectious diseases were no longer a major threat to mankind. This view was
supported by the successful eradication of smallpox. Unfortunately, the much lauded "health
transition" was founded on two false assumptions: that bacteria and other microbes were immutable
and unchanging and that outbreaks of disease could be sequestered. See Garrett, supra note 10.
51. For example, targeted federal funding for tuberculosis projects gave way to nonspecific
"block grants" that gave the states and local government discretion as to how the funds were used.
See Reichman, supra note 8, at 176.
52. Lemer, supra note 25, at 762. For example, the National Tuberculosis Association renamed
itself the National Tuberculosis and Respiratory Disease Association in 1968. Id.
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Many believed that the "white plague" had been effectively conquered. 3
"Doctors and the directors of public health programs tho'aght of it as a
defeated disease. They looked away."'
Despite the glorious success of antibiotic therapy, there were
indications as early as 1951 that TB had not retreated, but was merely
retrenching. By 1951, Mycobacterium tuberculosis was exhibiting
resistance to streptomycin, then the "first-line" antibiotic drug of
choice. 5 More important, even in the early 1950s, public health officials
experienced growing difficulty in exacting compliance as Ihey attempted
to deliver full courses of antibiotic treatment to infected persons.5 6 TB
was poised for a comeback.
B. Revitalizing Traditional Public Health Measures in the Face of
MDR-TB: A Futile Task
Tuberculosis was well on its way to reemerging as a major public
health risk by the 1970s. The incidence of TB in New York and other
urban areas in industrialized nations was slowly but steadily increasing,
as was the incidence in the developing world. In addition, a small but
significant percentage of never-treated new patients harbored drug-
resistant strains.57 Nevertheless, these danger signals failed to trigger a
53. Smith, supra, note 7, at 247. This misconception died hard. Throughout tI e 1970s and 1980s,
many public health authorities, including the U.S. Office of the Surgeon General, continued to
predict that, like smallpox, tuberculosis would be eradicated from the globe. In fict, during the Bush
Administration, the Centers for Disease Control assured state governments that fiscal commitments
dedicated to TB could be decreased because the threat was so diminished. Garrett, supra note 10.
54. Jonathan Weiner, The Beak of the Finch: A Story of Evolution in Our Time 261 (1994).
55. Smith, supra note 7, at 247.
56. Compliance presented problems for New York City's public health effort . even at the turn of
the century; the noncompliant "rounders" were detained and incarcerated in healthcare facilities, but
generally were released while still infected. The availability of antibiotics did not erase the
noncompliance problem. New York City municipal hospitals were able to discharge 9000
tuberculosis patients between 1950 and 1954; approximately one-third of these left against medical
advice and presumably before they had been rendered non-infectious. In addition, audits of
outpatient therapy revealed that noncompliance was common; in 1979, only 53% of cases followed
by the New York City Health Department had completed the full courses of outpatient treatment for
tuberculosis. Lemer, supra note 25, at 761.
57. This was particularly marked in New York, where 9.6% of new, never-ireated patients had
drug resistant strains, compared to a national average of 6.9%. The fact that these patients with
newly diagnosed TB had a resistant strain indicated that such resistant tuberculosis bacilli could be
transmitted directly and was not necessarily the product of prior inadequate treatment. As a result,
any individual, regardless of prior history of TB, may contract virulent MDR-TB Lerner, supra note
25, at 762.
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public health response." It was not until TB collided head-on with the
AIDS virus (HIV) that the depth and breadth of the "new" TB epidemic
gained public attention. 9 By the mid-1980s, MDR-TB was ravaging not
only HIV patients,' but also residents of correctional institutions,
patients in hospitals and other healthcare facilities,6 chronic abusers of
alcohol and drugs,62 and other immunosuppressed persons.63 Between
1981 and 1991, tuberculosis increased 125 percent in New York City.'4
Many patients in the "new" TB epidemic had a disease that was resistant
to the first-line drug therapies.6
Moreover, the dangerous MDR-TB could be transmitted directly from
the MDR-TB patient to a patient uninfected with any tuberculosis
58. Lerner, supra note 25, at 762.
59. See id.; see also Karen Glanz & Haiou Yang, Communicating about Risk of Infectious
Diseases, 275 JAMA 253 (1996) (discussing role of media in informing and awakening public as to
perils of infectious diseases including tuberculosis).
60. See Consuelo Beck-Sague et al., Hospital Outbreak ofMultidrug-Resistant Mycobacterium
Tuberculosis Infections: Factors in Transmission to Staff and HIV-Infected Patients, 268 JAMA
1280 (1992); Charles L. Daley et al., An Outbreak of Tuberculosis with Accelerated Progression
Among Persons Infected with the Human Immunodeficiency Virus, 326 New Eng. J. Med. 231
(1992); Maria de Lourdes Garcia Garcia et al., Epidemiology ofAIDS and Tuberculosis, 29 Bull. Pan
Am. Health Org. 37 (1995).
61. See Stephen Luby et al., A Nosocomial Outbreak of Mycobacterium Tuberculosis, J. Fam.
Prac., July, 1994, at 21; Michele L. Pearson et al., Nosocomial Transmission of Multidrug-Resistant
Mycobacterium Tuberculosis: A Risk to Patients and Health Care Workers, 117 Annals Internal
Med. 191 (1992); Sarah E. Valway et al., Multidrug-Resistant Tuberculosis in the New York State
Prison System, 1990-1991, 170 J. Infectious Diseases 151 (1994); see also Ruth E. Brown et al.,
Health-Care Expenditures for Tuberculosis in the United States, 155 Archives Internal Med. 1595
(1995).
62. See Keith Brndney & J. Dobkin, Resurgent Tuberculosis in New York City: Human
Immunodeficiency Virus, Homelessness, and the Decline of Tuberculosis Control Programs, 144
Am. Rev. Respiratory Diseases 745 (1991); Centers for Disease Control, Crack Cocaine Use Among
Persons with Tuberculosis-Contra Costa County, California, 1987-1990, 40 Morbidity &
Mortality Wkly. Rep. 485, 485-87 (1991). The risk of tuberculosis in substance abusers is
undoubtedly linked to their higher risk of HIV, or incipient HIV, and homelessness. Rothenberg &
Lovoy, supra note 29, at 723. The risk is further magnified by the fact that these patients frequently
are unaware of their increased susceptibility to tuberculosis. Salynn Boyles, At-Risk Populations
IVDUs Need More Information about TB, TB Wkly., July 31, 1995, available in WESTLAW, 1995
WL 10089953.
63. One such immunosuppressed group is the homeless, who frequently fall through the cracks of
TB treatment and develop MDR-TB. See Rebecca Voelker, New Push to Control Drug-Resistant TB,
Am. Med. News, Jan. 20, 1992, at 3. Another group frequently prone to increased risk on the basis of
immunosuppression is the chronically ill elderly. See Centers for Disease Control, Prevention and
Control of Tuberculosis in Facilities Providing Long Term Care in the Elderly, 39 (RR-10)
Morbidity & Mortality Wkly. Rep. 7 (1990).
64. See The World as a Hot Zone: New and Re-Emerging Diseases, Vaccine Wkly., Mar. 20,
1995, available in WESTLAW, 1995 WL 10090736, at *4.
65. Iseman, supra note 9, at 2429.
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infection.66 MDR-TB does not necessarily require the new victim to be
immunocompromised nor is it limited to those who acquire it by failing
to comply with treatment regimens. 67 Already, several U.S. cities, 6 as
well as far flung comers of the world, have witnessed mini-epidemics of
MDR-TB.69 Such outbreaks are not limited to the slums; there have been
documented cases of MDR-TB transmission on commercial airline
flights,7" in suburban high schools,71 and among church choirs.72
Confronted with an impending epidemic, most public health
authorities sought to counter resurgent tuberculosis by reinstating
modernized versions of the classic public health measures to detect
infected and at-risk persons and to provide treatment, using coercive
measures if necessary.73
1. The Challenge ofDetection
Detection and diagnosis of tuberculosis is a multistage process. The
initial method of screening for potentially infected patients is the
tuberculin test.74 A positive tuberculin, however, does not conclusively
establish that the patient suffers from active TB. Once the test is positive,
66. Id.
67. For example, one study of 25 patients with MDR-TB who were not HIV positive found that
only eight of them had a history of inadequate treatment for tuberculosis and nine of them had
known exposures to MDR-TB patients as healthcare workers (eight) or fellow patients (one). Three
of the remaining patients were residents of a homeless shelter. However, fotr patients had no
previously established risk factors for tuberculosis. See Edward E. Telzak et al., Multidrug Resistant
Tuberculosis in Patients without HIVInfection, 333 New Eng. J. Med. 907, 909-10) (1995).
68. See Centers for Disease Control, Outbreak of Multidrug Resistant Tuberculosis-Texas,
California and Pennsylvania, 264 JAMA 173 (1990) (reporting outbreaks of MDR-TB, each traced
back to index patients and perpetuated by their contacts); U.S. Reports TB Outbriak Killed 29 of32
Patients, Chi. Trib., July 14, 1993, at C7 (reporting outbreak of drug resistant TB in New York
hospital).
69. See Iseman, supra note 9, at 2429; Rise of Drug-Resistant Tuberculosis Alarms Thai Doctors,
Agence France-Presse, June 30, 1995, available in WESTLAW, 1995 WL 7823493.
70. Centers for Disease Control, Exposure of Passengers and Flight Crew 'o Mycobacterium
Tuberculosis on Commercial Aircraft, 1992-1995. 273 JAMA 911 (1995); Cynthia R. Driver et al.,
Transmission ofMycobacterium Tuberculosis Associated with Air Travel, 272 JA.MA 1031 (1994).
71. California School Becomes Notorious for Epidemic of TB, N.Y. Times, July 18, 1994, at Al.
72. Reichman, supra note 8.
73. See Josephine Gittler, Controlling Resurgent Tuberculosis: Public Health Agencies, Public
Policy and the Law, 19 J. Health Pol. Pol'y & L. 107, 124 (1994).
74. The tuberculin test consists of an intradermal injection of a purified protein derived from
tuberculosis cultures that is usually injected into the skin of the forearm. If the injection produces a
significant inflammatory reaction after two days, the test is positive for tuberculosis infection.
Isselbacher et al., supra note 17, at 714-15.
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diagnosis hinges on positive x-ray findings and evidence of active
tuberculosis bacilli in the lungs. This requires a positive culture of
respiratory secretions, a process that routinely requires three to six
weeks; conclusive diagnosis of MDR-TB requires even more time, often
two months or more.7"
This initial tuberculin test typically is administered as a screening
device to individuals in certain at-risk groups, such as health-care
workers, nursing home residents, and prisoners. Forty-four states provide
for required screening of such groups. 6 Such compulsory testing
measures generally have been upheld in the courts on the grounds that
the tuberculin test is relatively noninvasive and has a low risk of adverse
side effects."
Most TB screening programs are passive in nature-that is, they rely
upon at-risk individuals seeking screening or being placed in a situation
where screening is advantageous." Unfortunately, reliance on passive
screening means that many, if not most, at-risk patients escape screening.
Many of those at risk for tuberculosis have little or no access to acute
health-care services, let alone services aimed at prevention and
screening.79 Homeless persons, alcoholics, or intravenous drug abusers
are unlikely to receive the tuberculin test and even less likely to have the
results read in a timely fashion or to pursue additional testing. 0 Other
75. See id. at 714. Until very recently, the research underlying the diagnosis of tuberculosis was
several decades old and unaffected by newer biotechnologic techniques. The vast majority of
diagnoses are still derived using these time-consuming methods. Brown, supra note 3. Recently
available techniques have improved the length of time for MDR-TB diagnosis to about three weeks.
Lawrence 0. Gostin, Tuberculosis and the Power of the State: Toward the Development of Rational
Standards for the Review of Compulsory Public Health Powers, 2 U. Chi. L. Sch. Roundtable 219,
229 (1995). Even at three weeks, however, there is an appreciable risk of the patient failing to follow
through or otherwise being lost to follow-up.
76. See Gostin, supra note 75, at 249.
77. Id.
78. See Gittler, supra note 73, at 116. For example, one group typically screened are persons
working in the healthcare industry. Such healthcare workers will be predisposed to agree to
screening programs by virtue of their medical knowledge and the fact that it is a requirement for
employment in their profession.
79. For example, in the United States, approximately 20% of the population is uninsured. See
Laurie Abraham, Tough Times Ahead, 14 Bus. & Health 59 (1996). In addition, an even greater
percentage of the population is "underinsured"--that is, they may have baseline coverage that does
not include preventive health and screening measures. Twenty-seven percent of Americans cannot
depend on consistent healthcare coverage. See Frederick Schmitt; 67M in U.S. Had Lapse in Health
Cover, Nat'l Underwriter Life & Health-Fin. Servs. Edition, July 8, 1996, at 2. Elsewhere in the
world, particularly in developing nations, healthcare services may be inaccessible or non-existent.
80. These patients frequently are unreliable as a result of their substance abuse disorders,
underlying mental illness, and lack of options for transportation to and communication with health-
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vulnerable patients frequently lack insurance coverage for health-care
services or lack access, despite having such coverage.8 Unfortunately,
these are the very patients who are most prone to tuberculois.82
Another difficulty in detecting tuberculosis is that the tuberculin test
may fail to reveal the presence of infection when the patient is
mimunosuppressed" Such "anergy" is common in the elderly and in
patients afflicted with chronic or debilitating diseases.' The hallmark of
AIDS is massive immunosuppression; as a result, HIV-positive patients
are prone to test falsely negative upon tuberculin testing."5  This
propensity to false negative tuberculin testing is doubly dangerous, given
that immunosuppressed patients, especially those with AIDS, are at high
risk for exposure to tuberculosis and development of drug resistant forms
of the disease.86 Such patients frequently are not detected until their
tuberculosis infection is fully established, or even fulminant in nature.
Not only is tuberculosis more difficult to treat in its more advanced
stages, but the patient has had greater opportunity to serve as a vector,
disseminating active tuberculosis to family members, caretakers, and
others in his or her personal orbit.
care facilities and providers. Such a patient might have a tuberculin test placed, but not return for the
follow-up reading of the results; likewise if the test is positive, the patient might not appear for the
radiographic and laboratory studies. With several stages necessary for the diagnc.stic process, many
at-risk patients never attain diagnosis, let alone treatment of their tuberculosis. See Stephen E. Weis
et al., The Effect of Directly Observed Therapy in the Rates of Drug Resistance i, Tuberculosis, 330
New Eng. . Med. 1179 (1994).
81. Among the vulnerable populations are racial and ethnic minorities; they comprise 70% of TB
patients. In fact, there is some research data that indicates that certain minorities may be genetically
more susceptible to tuberculosis. However, it is more likely that the increased susceptibility is due to
a variety of social, economic, behavioral, and biologic factors. See The NHLBI Working Group,
Respiratory Diseases Disproportionately Affectfng Minorities, 108 Chest 1380 (1995). These
vulnerable patients frequently reside in a crowded, substandard living situation tlat is ideal for easy
transmission of tuberculosis. Rothenberg & Lovoy, supra note 29, at 722. Moreover, these are the
very populations that lack adequate insurance coverage for healthcare service. Similarly, the
homebound elderly person, who may live in a lower socioeconomic neighborhood, be
immunologically compromised as a result of age and chronic illness, and be well enough to shop and
ambulate in the immediate neighborhood (where TB is prevalent), may face transportation and
financial barriers in obtaining routine non-emergency health care.
82. Rothenberg & Lovoy, supra note 29, at 722.
83. See Isselbacher et al., supra note 17, at 715.
84. Anergy is the incapacity of the patient to mount a reaction to the tuberculin test despite the
fact the tuberculosis is indeed present. Approximately one-third of patients with new tuberculosis
exhibit anergy upon tuberculin testing. Anergy is associated with immunocompromised states.
Elderly patients, children, and infants frequently exhibit anergy as do patients suffering from chronic
illness. See id. at 715.
85. See id.
86. See Iseman, supra note 9, at 2429; Telzak, supra note 67, at 907.
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The problems with detection are exponentially increased in the
undeveloped and still developing comers of the world. These countries
frequently have little or no public health resources with which to mount a
tuberculosis-screening program." Indeed, the health-care system for
caring for acute medical problems may be rudimentary, and then
available only to certain urban cores of the population. The
transportation difficulties, scarce medical facilities and personnel, and
poverty in these nations make diagnosis of tuberculosis at an early stage
unlikely, if not impossible.
2. Assuring Treatment: The Role ofDirectly Observed Therapy
Once the tuberculosis patient is identified, he or she must submit to
treatment. Ideally, if the tuberculosis infection is latent rather than active,
and is due to a strain of tuberculosis that is not drug-resistant, the patient
will be able to forestall development of active tuberculosis by completing
a twelve-month course of isoniazid 8" Treatment of active tuberculosis
infection requires a more rigorous course of antibiotic therapy. Patients
with active TB that is not MIDR-TB are treated with several drugs,
including isoniazid and rifanpin, for a minimum of six months.8 9
It is an onerous regimen, replete with significant inconvenience and a
number of unpleasant side effects.9" The beleaguered patient frequently
decides that the cure is worse than the now asymptomatic disease and
87. For example, in Asia, where the tuberculosis epidemic is most severe, most Asian
governments have not undertaken significant public health efforts. See U.S. Dep't of Health &
Human Servs., supra note 12, at 108.
88. Such chemoprophylaxis is prescribed when the patient tests positive with a tuberculin test, but
otherwise tests negative for tuberculosis. Chemoprophylaxis is indicated for all patients under the
age of 35 and for patients belonging to risk groups who demonstrate a positive tuberculin test.
Isselbacher et al., supra note 17, at 717.
89. There are a number of drug regimens that effectively treat tuberculosis; all contain a minimum
of two drugs, usually rifampin and isoniazid. The usual course of treatment requires the patient to
take these two medications for six to twelve months. Additional or different drugs are required when
there is a need to shorten the course of treatment, when the patient is at risk for MDR-TB, when the
patient is afflicted with IV, renal failure, or other maladies that affect response to the drugs, or is
pregnant, Id. at 716.
90. Side effects of first-line drugs include hepatitis, peripheral neuropathies, fever, and flu-like
symptoms. Unfortunately the liver toxicity and hepatitis associated with isoniazid and similar drugs
is a particularly common side effect in Asians; approximately 30% of Asian patients develop this
adverse effect, making treatment in the TB-endemic areas of Asia even more difficult. See id.
Deafiess and renal impairment are associated with streptomycin and most of the second-line drugs.
Other deleterious side effects may also occur, but are less common. Id at 715.
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stops taking the medications? ! During a hiatus from treatment, the
partially treated, still-infectious patient contributes bacilli to the airborne
epidemic. Worse still, the result of incompleted treatment may be the
patient's conversion to more active disease status or infection with a
more virulent, drug-resistant strain of tuberculosis.92 When the patient
has contracted MDR-TB, the treatment includes the major first-line
drugs, plus additional "second-line" drugs; in MDR-TB, the duration of
treatment may be as long as twenty-four months.93
Regardless of whether the TB strain is drug resistant or not, the
multiple drug regimen must be carefully adhered to by the patient in
order to work. Although adherence to the medication regimen in
"regular" TB will produce a cure in virtually all cases, patients with
MDR-TB have a much worse prognosis. The mortality rates for HIV
negative patients are as high as forty-six percent; up to seventy percent of
HIV-positive patients with MDR-TB will die from it.94
As a result of patient noncompliance and the public health risk it
presents, public health authorities have sought to improve compliance by
monitoring treatment through directly observed therapy (DOT).95 In DOT
91. Patients frequently fail to finish their treatment program. Default rates as high as 40% to 60%
are not uncommon; rarely is the default rate less than 15%. Most of the defaults o,:cur within the first
six months of therapy. As a result, more intensive short-course regimens have been developed in the
hopes that patients will be more likely to compl-te the course. See id. at 716. Psychiatric disease,
alcoholism, drug addiction and other substance abuse, and homelessness are all positively correlated
with noncompliance. Age, sex, religion, education, race, and socioeconomic status are not positively
correlated with compliance. See Weis, supra note 80.
92. When a patient has a recurrence of tuberculosis, after having failed to adhere to their past
treatment regimen, the likelihood of the recurrence being due to drug resistant tLberculosis is about
two chances in three. Isselbacher et al., supra note 17, at 717.
93. Five major drugs are available to treat TB: they are streptomycin (the first anti-TB drug,
discovered in 1944 by Waksman), isoniazid (INH, a 1912 drug rediscovered in the 1950s and found
to be effective against TB), ethambutol (1950s), pyrazinimide (PZA, developed in the 1960s), and
rifampin (1972). Tuberculosis strains frequently have developed resistance to two or more of these
drugs. There are also several second-line drugs, including para-amino-salicylic acid, ethionamide,
cycloserine, capreomycin, kanamycin and amikacin, thioacetazone, rifabutin, and quinolones;
tuberculosis has developed resistance to these drugs as well. See Isselbacher et al., supra note 17, at
715.
94. Marian Goble et al., Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to
Isoniazid and Rifampin, 328 New Eng. J. Med. 527, 530 (1993). The more drugs the patient is
resistant to, the higher the mortality rate. Sriram Prasad Tripathy, Multidrug-resistant Tuberculosis,
World Health, July-Aug. 1993, at 19.
95. Although DOT has become part of the vernacular associated with the curre it TB epidemic, its
origins date back to the late 1940s and early 1950s, where it was used successfully by British
researchers to treat patients in Africa, Asia, and London. It also demonstrated successful results
when it was implemented on a small scale in the United States during the same era. See Ronald
Bayer & David Wilkinson, Directly Observed Therapy for Tuberculosis: Histoy of an Idea, 345
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programs, public health workers visually supervise the patient, verifying
that the patient is indeed taking the prescribed medications. This
observation may be accomplished by either having the patient report to
the clinic or treatment facility, or alternatively, by having the public
health worker visit the patient and observe administration of the
medication. 9
6
Diligent DOT programs produce excellent results. For example, one
DOT program attained treatment completion rates as high as 96.5
percent, coupled with a thirty percent decrease in new cases of TB-a
dramatic testimony to the effectiveness of the program in preventing and
curing tuberculosis.97 In addition, DOT is a cost-effective alternative to
hospitalization.98 Treating a "regular" TB patient in a DOT program will
cost approximately $600, while hospitalization for the treatment will cost
$25,000. When the patient has MDR-TB, the cost of both DOT and
hospitalization is multiplied by a factor often.9
Only a minority of the world's patients, however, have access to DOT
programs." And although DOT is a community-based service that can
be coordinated with other social services, many areas in which TB is
endemic have no such community and social services. In industrialized
countries, local governments may choose to fund programs serving other
constituencies deemed more worthy of limited resources; alternatively, in
countries like Great Britain, which have long-standing national health
programs, the political impetus for an adjunctive DOT program may be
lacking .11
Lancet 1545 (1995). However, DOT was believed to be too costly and labor intensive for widespread
use, until desperation caused New York and other urban U.S. cities to try DOT programs. See Morse,
supra note 5, at 719.
96. This visitation may take place at the residence, workplace, or other agreed-upon site (shelter,
school, food bank, etc.). Successful DOT program are flexible, seeking out the TB patients in tent
cities, approaching those working the streets, and offering incentives of food to encourage
compliance. See Scott Winokur, Traveling With the TB Trolley, S.F. Examiner, Sept. 14, 1993, at
A19.
97. Rothenberg & Lovoy, supra note 29, at 727.
98. A DOT public health worker who prevents even two hospitalizations justifies the cost of the
worker's salary. Seven hundred patients can be treated in a DOT program for what it would cost to
hospitalize just one patient with MDR-TB. See Morse, supra note 5, at 719.
99. Rothenberg & Lovoy, supra note 29, at 728.
100. In the United States, approximately 15% of patients are involved in DOT programs. Id. at
727. However, as noted infra note 126 and accompanying text, 97% of patients with tuberculosis are
located in the developing world, where intensive DOT programs are not feasible.
101. See Morse, supra note 5, at 719.
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In developing nations, the community bureaucracy necessary to mount
a DOT program does not exist. In many of these nations, legions of
tuberculosis patients are scattered over a wide, often perilous span of
geographic territory. The sheer size of such a program, combined with
the absence of funding, facilities, personnel, and medications, is a
daunting barrier to widespread implementation of DOT. 0 2
Moreover, DOT does not assure patient compliance with a treatment
regimen. TB patients are frequently members of a shadow society. They
may be homeless or lack a permanent address; in such cases, it is easy for
the patient to drop out of sight and out of the DOT programn.' O3 They may
be intravenous drug abusers who resume their drug habits. Similarly, the
recent immigrant" may choose to return to his or her homeland or join
other friends or relatives in another town or state, without: informing the
program.'0 5 In some of these cases, the public health authorities may
consider the patient such a risk that coercion and detention is sought to
ensure that the patient is adequately treated.
3. Enforcing Treatment: Detention and Coercion
Although the quarantining of infectious-disease patients was an
effective strategy earlier in this century, it is a tarnished alternative
today. Many states and local governments have long-standing, albeit
somewhat dated, statutes providing for the detention and treatment ofinfectious tuberculosis patients."16 Ii the past several years, several states,
including Washington," 7 have retooled their statutes, updating the
provisions to withstand modem legal scrutiny.' 8 However, even
disregarding the individual rights and due process concerns,' 09
quarantining of patients is no panacea.
102. Id.
103. See Winokur, supra note 96.
104. In 1993, 29.6% of reported tuberculosis cases in the United States occurred in persons born
outside the United States; overall foreign-born persons account for 60% of the increase in
tuberculosis cases from 1986 to 1993. See Raviglione, supra note 6, at 223.
105. For example, one study documented that 89% of patients being teated in a Harlem
treatment program were ultimately lost in follow-up. See Brudney & Dobkin, supra note 62, at 747.
106. See Gostin, supra note 29, at 255,257-58.
107. Id. at 255.
108. See generally Lisa A. Vincler & Deborah L. Gordon, Legislative Reform of Washington's
Tuberculosis Law: The Tension Between Due Process and Protecting the Public Health, 71 Wash. L.
Rev. 989 (1996). For a discussion of due process issues arising in the context of existing TB control
laws and proposals for reform, see Gostin, supra note 29 and Gostin, supra note 75.
109. See infra part III.C.2.
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History has shown us that isolation of patients did not quell the
tuberculosis epidemic of the past. Although it created a long-term care
system for some victims, sanitarium treatment did not prevent patients
from returning to their communities still infected and contagious. The
abeyance of tuberculosis in the first half of this century was not the result
of treatment in a quarantined setting, but rather a combination of
improved living conditions, a general waning of the disease entity, and
the discovery of antibiotics."'
Further countering the wisdom of quarantining large numbers of
patients is the cost and availability of modem inpatient care. Costs of
such care have escalated dramatically over the past several decades; the
cost of treating tuberculosis on an inpatient basis may be as high as a
$250,000.' Moreover, the increasingly cost-conscious health-care
industry has spent the last decade decreasing the supply and staffing of
inpatient units, often replacing inpatient facilities with outpatient
clinics."' Any move to return to an inpatient model, even in a case as
specialized as TB, diametrically opposes market-borne trends of the past
several years."'
Unfortunately, such fundamental, systemic barriers limit the promise
of all of the public health strategies described here. This becomes
glaringly obvious when one considers the tuberculosis epidemic not from
the local public health perspective, but as a worldwide global epidemic
inherently linking industrialized countries to the developing and
undeveloped nations of the world.
III. FUNDAMENTAL BARRIERS TO APPLICATION OF PUBLIC
HEALTH STRATEGIES ON A GLOBAL BASIS
Our world has changed materially from the world that dealt with
tuberculosis in the last century. Fundamental obstacles make efficient
comprehensive treatment of TB patients on a worldwide basis virtually
impossible. These obstacles include: an inadequate international public
health infrastructure in developed and developing nations alike;
110. See supra notes 37-49 and accompanying text.
111. Rothenberg & Lovoy, supra note 29, at 728.
112. See Russell C. Coile, Jr, Assessing Healthcare Market Trends and Capital Needs: 1996-
2000, Healthcare Fin. Mgmt., Aug. 1, 1995; Price Colman, State Hospitals Continue to Shrink:
Outpatient Increases Show Growing Trend Toward Managed Care, Rocky Mtn. News (Denver),
June 8, 1995, at 51A.
113. See generally Coile, supra note 112; Michael S. Jacobs, When Antitrust Fails: Public Health,
Public Hospitals, and Public Values, 71 Wash. L. Rev. 899 (1996).
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increasing and virtually uncontrollable mobility facilitating the spread of
tuberculosis; enhanced individual rights mitigating against coercive
treatment tactics; the prohibitively high cost of treatment, especially for
developing nations; and finally, that the available drugs and vaccines are
outmoded and wholly inadequate to meet a global threat of this
magnitude.
A. Public Health Infrastructure: Reconstructing a Relic'?
Throughout the world, the public health infrastructbre i t4 has been
allowed to deteriorate, while resources have been diverted to other needs
perceived to be more compelling."5 In large measure, public health is a
victim of its own success; having vanquished devastating infectious
diseases early in the twentieth century, it has turned to other serious, but
more ubiquitous, healthcare issues." 6 As a result, most nations, both
industrialized and developing, are ill equipped to meet the global
epidemic of resurgent and drug resistant tuberculosis." 7
Consider first the United States as a prototypical. industrialized
country. Its public health infrastructure, long dismantled, must be
reconstructed" 8 to deal with increasing numbers"9 of tuberculosis
114. Public health infrastructure has been defined as: "individuals and institutions that, when
working effectively together, promote and protect the health of people. The public health system in
America consists of the strategies, facilities, the material resources and, above all, the human
resources committed to transforming our national health." William L. Roper et al., Strengthening the
Public Health System,107 Pub. Health Rep. 609 (1992).
115. See Lederberg, supra note 9; Philip R. Lee, The Evolution of Public Health, 272 JAMA 1315
(1994). The complacency that fostered this deterioration has also contributed to lack of compliance
with medication programs and abuse and ovense of antibiotics. Lederberg, stpra note 9; See also
Brudney & Dobkin, supra note 62, at 748.
116. Alfred Sommer, Whither Public Health, 110 Pub. Health Rep. 57 (1995). Many of the
problems that have been embraced by the public health movement are deeply rooted in societal
determinants, for which successful intervention is undefined. This results in pre.eious resources being
devoted to problems which cannot be resolved at the expense of problems which might be alleviated.
Id.
117. Worldwide disease surveillance is inadequate and deteriorating; this is largely due to a lack
of a public health infrastructure to underpin such an endeavor. In most cases, although the public
health infrastructure can respond to a short-term emergency crisis, it cannot sustain the vigilant effort
that is required for a long-term global threat such as tuberculosis. See generaly Charles Marwick,
Effective Response to Emerging Diseases Called An Essential Priority Worldwide, 273 JAMA 189
(1995).
118. For a discussion of how such a reconstruction could be effected in the age of healthcare
reform, see Philip R. Lee & Kathleen E. Toomey, Epidemiology in Public Health in the Era of
Health Care Reform, 109 Pub. Health Rep. 1 (1994). See also Kristine Gebbie, Rebuilding a Public
Health Infrastructure, 21 J.L. Med. & Ethics 368 (1993); Margaret A. Hamburg, Rebuilding the
Public Health Infrastructure: The Challenge of Tuberculosis Control in New Ycrk City, 21 J.L. Med.
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patients, including a substantial percentage of patients who have MDR-
TB. This would be a formidable struggle even if public health authorities
could use the techniques of isolation and comprehensive, medically
controlled treatment. However, the public health strategies that forced
tuberculosis into retreat in the past no longer have the same vitality.
Many public health functions have been subsumed by the private
health-care systems over the last several decades. In the United States,
the private health-care system is only just beginning to adopt principles
of preventive health care and total case management. Whether the new
managed-care arrangements and health plans will be able to deal
effectively with public health threats like tuberculosis remains to be
seen.
2 0
Other industrialized nations have also allowed their public health
infrastructures to languish, 2 1 although it is possible that the universal
health-care systems found in nearly all industrialized nations will
substantially aid mounting public health efforts. In these nations, all
persons have access to basic healthcare services regardless of social or
financial status. 22
It is unlikely that funds will be allocated to resuscitate the public
health infiastructure to a level that could counter the threat of
tuberculosis and other emerging and reemerging infectious diseases. In
1994, the Centers for Disease Control (CDC) announced a plan to
upgrade public health measures and the accompanying infrastructure for
this purpose. The proposed plan had a price tag of $125 million per year;
Congress appropriated only $7.7 million and the plan was dramatically
scaled back." On a global level, the World Health Organization has
& Ethics 352 (1993); Stephen C. Joseph, New York City, Tuberculosis, and the Public Health
Infrastructure, 21 J.L. Med. & Ethics 372 (1993); Roper et al., supra note 114.
119. TB is predicted to be responsible for 30 million deaths worldwide in the coming decade. See
Nakajima, supra note 5.
120. See Siege Relief, Am. Med. News, Jan 8, 1996, at 35. However, some postulate that unless
the public health system survives and strengthens to the point that it is able to effectively work with
private healthcare efforts, the private healthcare financing and delivery system will be overwhelmed
with illnesses and injuries caused by public health problems they are powerless to control. See
generally Edward L. Baker et al., Health Reform and the Health of the Public: Forging Community
Health Partnerships, 272 JAMA 1276 (1994).
121. See Earl S. Hershfield, Prevention in the Developed World, 346 Lancet 813 (1995).
122. All industrialized nations with the exception of the United States and South Africa have
universal healthcare systems providing care for their populations. Note, however, that several of the
systems, notably that in the United Kingdom, have recently sought to privatize certain segments of
health-care services.
123. Christina Kent, A Long-Neglected System Strains to Respond to a Rising Threat, Am. Med.
News, Jan. 8, 1996, at 9.
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declined to dedicate a significant portion of its budget to the TB
emergency. It provided six million dollars in aid targeted 5or TB in 1994,
but only fourteen percent of this came from WHO's budget; the
remainder was derived from donor nations.'24
In the case of the less developed countries, especially hose in Africa,
Asia, and South America, there is no vestige of a public health
infrastructure to revitalize. There are no medical personnel to treat the
patients, no facilities from which necessary medication might be
dispensed, and no centralized, computerized medical records system to
keep track of who was treated, their medical and social history, and
response to treatment. 21 In addition, inadequate living conditions
provide an even more significant barrier. In many of these countries, the
malnourished population lives in crowded, poorly ventilated, unhygienic
housing-an ideal breeding ground for tuberculosis bacilli. It is no
wonder that ninety-seven percent of tuberculosis cases occur in
developing countries. 126 Even when such a nation appreciates the
tuberculosis threat, the cost of identification and treatment of patients is
both overwhelming and secondary, when that nation may be struggling
simply to feed its citizens.
B. Global Ghettos and the Age of Geographical Mobility
Unlike the AIDS virus, TB is airborne, rather than blood-borne: "The
principal risk behavior for acquiring TB is breathing."' 27 In developing
countries, where TB is most prevalent, the rich breathe Ihe same air as
the poor; visitors from the developed world visit the slums as well as the
Hilton, even if they only pass through the same narrow street or use
public transit. Exposure to and the spread of tuberculosis is inevitable.'28
124. See Reichman, supra note 8, at 175.
125. See Ronald J. Waldman, Public Health Surveillance on the World Health Agenda, Speech
delivered at International Symposium on Public Health Surveillance, in 41 Mrbidity & Mortality
Wkly. Rep. 201 (1992) (describing information and system needs for world health surveillance). But
see Lawrence 0. Gostin et al., The Public Health Information Infrastructure: A National Review of
the Law on Health Information Privacy, 275 JAMA 1921 (1996) (discussing confidentiality and
privacy concerns of enhanced informational systems).
126. More than one-fifth of the 5.6 billion people in the world live in extreme poverty, almost a
third of the world's children are undernourished, and half the global population lacks access to
medications. See WHO Widening Gaps Between Rich and Poor Pose Global Health Threat, Vaccine
Wdy., May 1, 1995, available in WESTLAW, 1995 WL 10090893, at *1; se? also Brown, supra
note 3.
127. Weiner, supra note 54, at 261.
128. The role of travel and migration in the spread of tuberculosis has been appreciated since the
turn of the century. With the invention of the locomotive, rail travel brought tuberculosis to many
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The last several decades have seen world population growth coupled
with unprecedented travel and movement of people.'29 In 1994, thirty
million people moved from rural areas to urban areas within their own
countries; this intra-nation migration into urban ghettos fosters the spread
of tuberculosis. 30
Even more problematic for the dissemination of tuberculosis and other
infectious diseases is the ease and frequency of international travel.'
Every day, one million people cross an international border; one million
people a week traverse between the industrial and developing world.3 2 In
developing nations, even if tuberculosis medications are available, there
is no public health infrastructure to guarantee patient adherence or to
verify that travelers into these countries are not infectious. Recent U.S.
public health policies have espoused a need for improved global
surveillance, including closer scrutiny of persons and products crossing
national borders and enhanced dispersal of information with respect to
the risk of infectious disease transmission inherent in travel."' However,
as one prominent scientist has noted, such measures provide little safety
when a disease's incubation time exceeds that of air travel. 3 4
areas in which tuberculosis had been rare. Moreover, these new frontier areas frequently were unable
and unwilling to accept the chronically ill tuberculosis patient who stepped off the train. See
Rothman, supra note 7, at 190-91.
129. See Lederberg, supra note 9.
130. One of the greatest potential causes of infectious disease epidemics, including tuberculosis,
is the development of the third world and the urbanization of industrialized nations. As persons from
rural areas devoid of an infectious disease are exposed to urban areas rife with risk, the disease is
able to spread geographically. See International (North and South America) Spread of Infectious
Disease Continues, AIDS Wkly. Plus, June 3, 1996, available in WESTLAW, 1996 WL 2093337.
From 1950 to 1990, the world's urban population increased from 29% to 45% of the planet's
population. Concerned about the public health implications of this movement into cities, the world
Health Organization has urged nations to offer incentives to their citizenry to deter such migration.
Phil Gunby, 1992 Could Be Pivotal Year in Efforts to Improve Health of People Everywhere, 267
JAMA 15 (1992).
131. See Garrett, supra note 10; see also Mitchell L. Cohen, Epidemiology of Drug Resistance:
Implications for a Post-A ntimicrobial Era, 257 Science 1050 (1992).
132. See Garrett, supra note 10.
133. See Lederberg, supra note 9; Working Group on Emerging & Re-emerging Infectious
Diseases, National Science & Technology Council, Infectious Disease-A Global Health Threat (last
modified Nov. 7, 1996) <http://www.whitehouse.govWH/EOP/OSTP/CISET/htmVeiset.html>.
134. See Lederberg, supra note 9. Surveillance for infectious disease at airport entry ranges from
grossly inadequate to biologically irrational to non-existent. Infectious diseases may not be
symptomatic or evident for days, weeks, or months after entry. See Garrett, supra note 10. In the
case of TB, a patient would have to exhibit significant signs of active disease to be detected given
that rapid testing for the tuberculosis is unavailable.
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In addition to casual travel, at least 110 million people immigrated to
a new country in 1994.135 In most cases, the immigrant will be seeking a
better life by moving to an urban center in a more developed nation.
Even in the poorest of nations, a subset of the population will immigrate
to the United States and other industrialized nations, bringing TB
infection along as an unwanted companion.136
In the case of immigration to the United States, some individuals will
be diagnosed with tuberculosis and refused entry.'37 Nevertheless, many
entering the country will do so on short-term visas and will escape
screening and detection.3 In addition, some immigrants enter illegally.
In their quest to find a better life for themselves and their families, they
may not realize that part of their misery is due to tuberculosis
infection;'39 once they have successfully crossed the border illegally, they
are unlikely to draw attention to their presence by seeking care for
illness.
Even if a nation could sequester and adequately treat its own citizens
with TB, neither the United States aor any other nation cart insulate itself
from exposure to tuberculosis arriving with travelers and immigrants.
The obvious conclusion is that we cannot begin to control tuberculosis in
industrialized countries until we find a way to sharply decrease its
incidence in developing and undeveloped nations. 40 Absent some means
135. See Garrett, supra note 10.
136. Immigration from developing nations increases the risk of MDR-TB. The immigrant may
have received inadequate treatment prior to leaving the native country and may be incubating drug
resistant TB. The immigrant is likely to settle in an urban area, often in a enclave of other recent
immigrants who might harbor tuberculosis. In addition, the new immigrant may lack access to health
care in his or her new home and allow the disease to progress before seeking treatment. See Alan B.
Bloch et al., Preventing Multidrug Tuberculosis, 275 JAMA 487 (1996); Garrctt, supra note 10. In
the United States, for instance, foreign-born patents are markedly more prone to be diagnosed with
tuberculosis. U.S. Dep't of Health & Human Servs., Tuberculosis Morbidity-United States, 1994,
44 Morbidity & Mortality Wky. Rep. 387, 395 (1995). In New York, where the TB epidemic is
strongly identified with the incidence of IV and substance abuse, one-third of the patients are
foreign born. In other areas of the United States, TB primarily affects immigrant populations.
Similarly, in other industrialized nations, more than half of new TB cases are found among foreign-
born persons. WHO Urges Making Directly-Observed Therapy the Priority in Global Tuberculosis
Control; Praises New York as Model to Stop TB Epidemic, U.S. Newswire, Mar. 20, 1995.
137. See Sana Loue, Immigrants, Immigration Law, and Tuberculosis, 71 Wash. L. Rev. 969,
979-85 (1996).
138. See id.; Stephenson, supra note 8, at 1648.
139. See Stephenson, supra note 8.
140. Nakajima, supra note 5.
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to address TB more effectively and globally, the disease is predicted to
cause thirty million deaths over the next decade.141
C. Individual Rights and Due Process vs. Coerced Treatment and
Detention
Compounding administration of effective tuberculosis treatment is the
important question of individual rights and autonomy. A long legal and
cultural tradition in the United States recognizes the power of the state to
protect the public health even at the expense of individual liberty. Dating
back to the seminal case of Jacobsen v. Massachusetts,'42 public health
authorities have enjoyed support from the courts as they battled
infectious disease and other public health threats.'43 In the case of
tuberculosis, many states enacted targeted public health laws providing
for coerced treatment and detention, if necessary.'" Such laws were
upheld throughout the nineteenth and twentieth century, so long as the
state's power was not exercised in an arbitrary and capricious manner
and detention was based upon a reasonable threat.'45
However, the last few decades have witnessed greater weight
accorded to substantive and procedural due process. In the United States,
our doctrine of constitutionally guaranteed due process has evolved to
imbue the individual with rights of liberty and privacy that make
mandatory, enforced, long-term treatment and even enforced prophylaxis
legally problematic.'46
Thus, when coercive measures such as detention, quarantine, enforced
treatment or even directly observed therapy (DOT) are implemented,
public health officials and medical providers must walk a fine line
between administering necessary treatment and abridging the patient's
fundamental rights. Generally, treatment programs must be carefully
141. Id.
142. 197 U.S. 11 (1905). In Jacobsen, the Supreme Court held that a Massachusetts man had to
comply with a mandatory smallpox vaccination law, despite the fact that it infringed upon his
individual liberty rights. The Court reasoned that individual liberty rights may be curtailed under the
police powers of a state when the health and safety of the general citizenry are at risk. Id. at 26-27.
143. See Gittler, supra note 73, at 124.
144. See Gostin, supra note 29, at 257-59; Rothenberg & Lovoy, supra note 29, at 733-37.
145. Rothenberg & Lovoy, supra note 29, at 733.
146. For a detailed analysis of the interplay between individual rights to substantive and
procedural due process in the context of prevention and treatment of tuberculosis, see Gostin, supra
note 75.
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tailored to be no more coercive than can be reasonably justified by the
level of the threat.147
Industrialized nations frequently share the due process norms found in
the United States, even if their constitutions and laws do not specifically
articulate them. These nations too, while attempting to resuscitate long-
neglected public health strategies, are likely to find that expanded tenets
of individual rights foreclose use of even necessary coercive measures.
Developing nations and those still enmeshed in poverty may have
cultures and legal frameworks that are more accepting of coercive
techniques of tuberculosis screening, prevention, and treatment.
Tuberculosis is often rampant in these countries. However, these
countries frequently lack the economic resources to carry out programs
of the scope necessary to curb the incidence of tuberculosis within their
borders. In addition, because inadequate or incomplete treatment may
result in conversion to the more dangerous MDR-TB, it is possible that
harsh coercive programs in such developing nations might actually
worsen the epidemic.
D. Paying the Bill: The High Cost ofFighting a Global Epidemic
Using Current Strategies
Dealing with the tuberculosis epidemic on a global basi:s using current
detection and treatment techniques would require substantial medical
personnel, establishment of laboratory and other healthcare facilities,
drugs, vaccines and other treatments, and the logistical support to
disseminate them all. The cost of such a global program, even if it were
feasible, would be astronomical in today's high-cost health-care market.
In the United States, a subcommittee of the National MultiDrug
Resistant Tuberculosis Task Force determined that estimated
expenditures for treating TB in 1991 were $703.1 million with sixty
percent of the amount devoted to inpatient treatment, twenty-six percent
to outpatient treatment and the remaining fourteen percent used for
screening and preventive therapy activities.'48 The fact that the lion's
share of expenditures for TB are for inpatient care indicates that our
efforts to control the infections at an early, more easily treated stage, are
inadequate. Moreover, these costs are projected to grow to as much as
$2.2 billion by 2000.149 This astronomical sum will be needed just to
944
147. See Reilly, supra note 11, at 140-41.
148. Brown, supra note 61, at 1595.
149. Id.
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treat the tiny minority of the world's TB cases found in the United
States.150
Because of a major appropriation of cash and attention to the problem
of tuberculosis in New York and other U.S. cities, tuberculosis has begun
to decline, albeit only slightly.' However, even in the best of times, the
United States would be unable to fund unilaterally and supply such a
comprehensive program worldwide. '52 Even countries with national
health-care systems may have insufficient financial resources to provide
the extended, expensive medication regimen to TB patients, often their
poorest, most powerless citizens.
The cost of TB drugs is an unaffordable burden for many developing
countries--even aside from the costs of structuring a delivery system to
administer them reliably.'53 Drug-resistant strains of TB present a
virtually insoluble problem for such nations, given that the cost of
institutionally treating a single MDR-TB patient may rise to an estimated
$250,000.' Added to this is the cost of surveying compliance. DOT is
known to be cost effective and would prevent the costly complications of
hospitalization and progression to drag-resistant disease.'55 However,
even with the lower labor costs in many developing nations, the cost of
implementing such a massive program would be prohibitive for many
nations.'56
Nor is it likely that world relief organizations will be able to provide
the sufficient aid to curtail the tuberculosis epidemic in any meaningful
150. Id.
151. In the United States, there were 24,361 cases of active tuberculosis in 1994; a year later, as a
result of conscientious renewed public health efforts in cities like New York, the number decreased
to just under 23,000. See Thomas R. Frieden et al., Tuberculosis in New York City-Turning the
Tide, 333 New Eng. J. Med. 229 (1995); TB's Resurgence Calls for New Drugs, Seattle Post-
Intelligencer, Mar. 26, 1996, at A6.
152. See Lederberg, supra note 9. And these are not the best of times; like many other nations, the
United States faces an ever more constrained budget. Id.
153. Many developing countries tend to refrain from using rifampin, a more expensive drug, if
possible. Often, they instead use thiacetazone, a cheap but less effective anti-TB drug that also has a
propensity for fatal adverse reactions when administered to AIDS patients. In addition, because
developing countries are heavily dependent upon donor drug supplies from pharmaceutical
companies or other nations, they may have little control over the content and quantity of their supply
of anti-tuberculosis drugs. See Alwyn Mwinga, Treatment in Developing Countries, 346 Lancet 812
(1995); Brown supra note 3. Obviously this presents significant problems in Asia, where risk of
hepatic toxicity from isoniazid is high and access to rifampin limited; the net result is that
developing nations may find themselves deprived of both first-line drugs. See supra note 90.
154. Rothenberg & Lovoy, supra note 29, at 728.
155. See supra notes 97-102 and accompanying text.
156. See Morse, supra note 5, at 719.
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way. The World Health Organization, other medical aid organizations,
and industrialized donor nations cannot begin to cope with the massive
TB problem in the developing world. In 1990, when almost two million
people died of TB, only sixteen million dollars were funneled to the
developing countries where it is endemic. 5 7 In theory, this amount could
be consumed by fully treating only forty-eight MDR-TB patients in one
city of one developing nation. 58
Public health measures, even if funded at an adequate level in the
developed world, would still be hampered by the profound poverty and
abject living conditions that give rise to tuberculosis infection in
developing nations. The mobility of our modem world ensures
transmission. Thus, even if strenuous public health efforis temporarily
win the battle in New York and other U.S. cities, tuberculosis will
prevail in the global war.'59
Given the many roadblocks that stand in the way of implementing
public health strategies worldwide, we desperately need new weapons
with which to combat this versatile infectious enemy. In addition to new,
more rapid means of diagnosing T]3, new drugs are needed to prevent
and treat both the traditional and drug resistant strains. The new drugs
need to be capable of eradicating TB with a much more abbreviated
course of treatment than is required by the current agents, with fewer
side effects."6 Most importantly, they must be capable of mass
production at a reasonable cost. Moreover, efforts to find a vaccine that
can preempt infection altogether should be accelerated. The goal should
be to diagnose and treat or prevent tuberculosis over a very short
treatment time span, ideally one visit. Unfortunately, research and
development of modem tuberculosis treatment options remained locked
in the past, even as tuberculosis reemerged as a global public health
threat.
157. See Fighting TB-U.S. Must Join Global Health Effort, Dallas Morning News, Dec. 29,
1993, at 18A.
158. Moreover, in relative terms, the amount :f currently allocated aid is woefully inadequate
when compared to other medical problems of the developing world. For example, in contrast to the
$16 million allotted to TB in 1990, $77 million wzs devoted to treatment of leprosy, a disease which
claimed only 2000 lives that year. Id.
159. Tan, supra note 1, at211.
160. See Richard I. O'Brien, WHO's Role in Tuberculosis Research, World Health, July 1993, at
13.
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IV. TUBERCULOSIS DRUGS AND VACCINES: LOCKED IN THE
PAST
Research and development of new anti-tuberculosis drugs and
vaccines have been largely ignored for the last several decades. The sad
fact is that the last major first-line drug specifically approved for the
treatment of TB was rifampin."6' It was approved by the FDA in 1972,
although it had been marketed in Europe several years earlier.62 Recently
new combination medications, combining already approved anti-
tuberculosis drugs, have been marketed, 63 but for the most part, research
for new antibiotic agents has been stalled for many years." On the
vaccine front, the primary vaccine now available is Bacillus Calmette-
Guerin (BCG). BCG was originally developed from an attenuated live
vaccine derived from cows in the early twentieth century. When initially
developed, it was hoped that BCG would offer a safe and effective TB
immunization. Unfortunately, although BCG did evidence limited ability
to prevent infection, its performance was erratic and inconsistent.'
Initially it was plagued by a tragic research accident that colored the
view of BCG for many years.'66 Periodic reexamination of its utility has
not found any way to predict or standardize its effectiveness. Questions
regarding its variability and efficacy have remained unresolved. 167
Recently, however, in response to the gradually dawning realization of
the new TB threat, there have been fledgling efforts to renew research
161. Five major first-line drugs are available to treat TB; several second-line, less effective drugs
may also be used. See supra notes 89-90, 93 and accompanying text.
162. Reichman, supra note 8, at 175.
163. These drugs, Rifater, and Rifamate, contain two or more anti-tuberculosis drugs in one
capsule. They offer dosing advantages over multiple single agents. See id; Thomas Moulding et al.,
Fixed-dose Combinations ofAntituberculous Medications to Prevent Drug Resistance, 122 Archives
Internal Med. 951,951 (1995).
164. See WHO Accuses Industry oflndifference to TB Dilemma, Pharmaceutical Bus. News, Mar.
27, 1996, at 14.
165. At the time, this was thought to be due to a myriad of factors, not the least of which were the
technical limitations of the time. See Dubos & Dubos, supra note 7, at 163.
166. See generally supra notes 40-41 and accompanying text.
167. See supra notes 40-41 and accompanying text. A recent review of the literature indicated
that BCG significantly reduces the risk of TB, but that there is insufficient information to determine
its efficacy, especially as related to age of vaccination. Graham A. Colditz et al., Efficacy of BCG
Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature, 271 JAMA
698 (1994). Perhaps the greatest problem with BCG is the incredibly variable protection it
provides-ranging from zero to 80%. In seeking to clarify its efficacy, one study found that the
effectiveness of the vaccine appears to be affected by geography, sunlight, temperature,
manufacturing and storage conditions, and genetic factors. P.E.M. Fine, Variation in Protection by
BCG: Implications of andforHeterologous Immunity, 346 Lancet 1339 (1995).
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into anti-tuberculosis agents. Most of these have been initiated by
companies experienced in new biotechnologic techniques.16 Several
types of vaccines are being researched. They include an improved
version of BCG that has been genetically manipulated, a new live
vaccine consisting of a genetically altered non-virulent strain of TB, and
new DNA vaccines with specially coded genes.1 69 This new vaccine
research is heartening, especially because research for additional new
drugs has not been forthcoming during the decade of resurgent TB.
170
A. Social Barriers Hindering Newv Drug and Vaccine Development
A variety of social and financial barriers have allowed research for
new TB therapies to languish despite the growing incidence of the
disease worldwide. First and foremost, the tuberculosis epidemic has
failed to capture the attention of politicians; similarly, it has been unable
to stimulate a groundswell of public outrage. Its victims in industrialized
nations are no longer the interesting, intellectual writers and poets who
exemplified the nineteenth century victim.171 TB's new -victims are far
less socially acceptable. In the United States, tuberculosis patients are
typified by the chronic substance abuser who may also be infected with
AIDS; prison inmates; the homeless; or the recent, frequently non-
English speaking immigrant, who even as a legal resident is viewed as an
interloper.'72 None of these patients are perceived as sympathetic victims.
168. See Daniel J. DeNoon, New Strategies Revolutionize Vaccinology, Vaccine Wkly., Nov. 13,
1995.
169. M. Harboes, Novel Developments: Vaccines against Tuberculosis, Vaccine Wkly., Apr. 1,
1996.
170. See Joseph H. Bates, Tuberculosis Chemotherapy: The Need for New Anntuberculosis Drugs
is Urgent, 151 Ain. J. Respiratory Critical Care Med. 942, 943 (1995). Note however, that several
trials are ongoing with respect to new versions of existing drugs and combinations of existing drugs
to decrease the length and absolute number of doses to effect cure. See Reichmmn, supra note 8, at
175.
171. Many historians have commented upon the strange association between tuberculosis and
intellectual and creative activities, citing its mcre famous victims as examples: Voltaire, Keats,
Shelley, Robert Louis Stevenson, and Saint Francis of Asissi. See generally Lewis J. Moorman,
Tuberculosis and Genius (1940).
172. In the United States, 29.6% of tuberculosis cases occur in persons born outside the United
States. Raviglione, supra note 6, at 223. Foreign-born persons are increasingly viewed as outsiders
regardless of their immigration status, as is illustrated by the recent legislative proposals to limit
government benefits and other entitlements available to legal immigrants. Bruce B. Auster et al., A
Blizzard of Bills from Congress: Will Welfare Reform Worsen Life for the Poor?, U.S. News &
World Rep., Aug. 12, 1996, at 25; Faye Fiore, Welfare Reform Increases Health Risks, Experts
Warn, L.A. Times, Aug. 24, 1996, at A12; Janice Somerville, AMA: Maintain Health Care for Legal
Immigrants, Am. Med. News, July 17, 1995, at 5.
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Second, the vast majority of TB victims reside in the less developed
world. 73 No newsworthy flood, famine, or war brings them to the
attention of the powers and public consciences of industrialized nations
and the decision-makers within the pharmaceutical industry. TB is an
insidious, nondescript killer, claiming most of its three million victims
silently without drama or poster children. In short, TB is neither classy
nor mediaworthy.
Another social and cultural barrier results from tuberculosis's status as
an "old" disease. Perhaps because Americans and citizens of other
industrialized nations enjoy so many inventions never even dreamed of
by previous generations, they are extraordinarily enamored of that which
is "new." New technologies, new discoveries, and new diseases benefit
from this long-standing romance with the novel; old problems like
domestic violence and TB do not. Rather, old unsolved problems are
relegated to the depths of our cultural consciousness. The author submits
that a pivotal reason why TB vaccine research has been more active than
drug research is that the former offers the opportunity to use new,
scientifically "sexy" gene coding and biotechnology techniques.
B. Financial Barriers: Regulatory, Economic, and Marketing Issues
The social and cultural barriers are rivaled by a formidable regulatory
approval regime that is costly and time consuming. The regulatory
morass enhances the economic and marketing difficulties fueling
pharmaceutical industry reluctance to develop any product that is not
certain to be profitable and win regulaiory approval.
Although recent public policy reports have recognized that
pharmaceutical companies have an indispensable role to play in
defeating reemerging infectious diseases like tuberculosis, reports offer
no guidance as to how to finance the investment in research and
development of such products. 74 Generally research and development
for new pharmaceutical products will be undertaken only when the
investment will result in a significant profit margin.'75 In the case of
173. There is some evidence that tuberculosis undermines developing nations' efforts to build
more functional economies in that it strikes potential workers before or in their most productive
years. U.S. Newswire, supra note 136.
174. Lederberg, supra note 9; see also WHO Accuses Industry of Indifference to TB Dilemma,
supra note 164.
175. See Kent, supra note 123.
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tuberculosis, much of the market will be poor, profit is uncertain, and
costs of compliance with regulatory hurdles and legal liability are high.176
With both drug and vaccine development, pharmaceutical
manufacturers face difficult regulatory environments. This is particularly
true in the United States, but other industrialized countries also require
compliance with onerous approval processes. 177 Moreover, until very
recently, there has been little or no reciprocity among nations with
respect to approval processes for drugs and vaccines.
171
Recent efforts to standardize approval processes throughout European
Community nations have not yet been mimicked by the FDA, an agency
nicknamed the "foot-dragging and alibi" agency by its many
detractors.'79 The FDA process is the most conservative, arduous, and
time consuming of the world's drug approval processes; it has been
accused of "deadly over-caution" in the lay press,' not a wholly
undeserved label.
First of all, the FDA has more than one set of rules. It approves and
regulates drugs using one process mandated by the Food, Drug and
Cosmetics (FD&C) Act,'' biologics such as vaccines by another, the
Public Health Services (PHS) Act;' 2 and medical devices by a third, the
176. See Lederberg, supra note 9.
177. See generally Rosemarie Kanusky, Pharmaceutical Harmonization: Standardizing
Regulations among the United States, the European Economic Community, and Japan, 16 Hous. J.
Int'l L. 665 (1994).
178. See generally id.
179. Federal News Service, Hearing of the Oversight and Investigations Subo)mm. of the House
Commerce Comm., Feb. 29, 1996, available in WESTLAW, 1996 WL 5509259, at *146 (comments
by Chair of Subcomm., Rep. Joe Barton).
180. Carolyn Lochhead. "Deadly Over-Caution "/FDA Assailed for Slow Tesfing of New Drugs,
S.F. Chron., Oct. 26, 1992, at Al.
181. 21 U.S.C. §§ 301-393 (1996). The 1938 Food, Drug and Cosmetics (FD&C) Act superseded
the Food and Drug Act of 1906, expanding the scope of product regulation dramatically. The 1938
Act imposed requirements upon drug manufacturers to file a new drug application before they
marketed their products to the public. A series of amendments have modified and further expanded
the scope of the 1938 Act, usually enacted in response to the expanding frontiers of science. These
range from amendments added in 1941 to address a new biologic, insulin, to the Prescription Drug
User and Generic Drug Enforcement Acts of 1992. Throughout its long history, the FDA has focused
on regulating food and drug manufacturing to ensure safety and effectiveness. See Alan H. Kaplan,
Fifty Years of Drug Amendments Revisited: In Easy-to-Swallow Capsule Form, 50 Food & Drug L.J.
179 (1995).
182. 42 U.S.C. § 262 (1994). Curiously, the statutory provisions governing biologics like
vaccines actually predate the 1906 Food and Eug Act. Congress took action to regulate such
biologics in 1902 after a number of highly publicized deaths resulted from contaminated smallpox
vaccine. Despite the early legislative action and statutory authority, regulatior of biologics was
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Medical Devices Amendments (MDA).18 3 In the case of many biological
products, the FDA exerts authority over the product, requiring
compliance with both the PHS and FD&C Acts.'
14
The complications presented are readily evident by reviewing the
approval process for a new drug-the least complicated of the regulatory
regimens. The FDA has rigorous safety and effectiveness standards
guaranteed by a lengthy four-stage approval process applied to new
drugs. This FDA regimen proceeds from an initial pre-clinical testing
phase performed on animal subjects, followed by an investigational new
drug (IND) phase with three stages of clinical trials on human patients.
The accumulated data is then submitted to the FDA in a new drug
application (NDA) for evaluation, review and additional safety and
effectiveness testing prior to FDA approval.18 This extended process
routinely takes a decade or more to complete and is extremely costly for
the pharmaceutical manufacturer.'86 After approval, the fourth phase
commences: it consists of post-marketing surveillance and monitoring of
the drug's safety and efficacy.'87
Partially because of the high costs of research, development, and
approval for new drugs, the pharmaceutical industry focuses on the
markets in industrialized nations.'88 These are the nations that provide
largely unenforced until the 1950s. Gary E. Gamerman, Regulation of Biologics Manufacturing:
Questioning the Premise, 49 Food & Drug L.J. 213 (1994).
183. 21 U.S.C. § 360 (1994).
184. For discussion of the relationship and interplay between the FD&C Act and the PHS Act
provisions, see Edward L. Korwek, Human Biological Drug Regulation: Past, Present, and Beyond
the Year 2000, 50 Food & Drug L.J. 123 (1995). Korwek notes that biologics products are
simultaneously either biologics and drugs or biologics and devices under existing law. Thus, the
major distinction is whether or not the contemplated product is a biologic; if so, it will be susceptible
to two sets of regulatory requirements. Id. at 128. Another layer of complication is that within the
regulatory bureaucracy, separate regulatory centers deal with different FDA products. Drugs are
evaluated by the Center for Drug Evaluation and Research (CDER) and biologics by the Center for
Biologics Evaluation and Research (CBER). See Gamerman, supra note 182, at 213-16.
185. The delays and time required in the current process are inextricably linked with cost.
Industry experts report that taking the average drug from laboratory to market costs $400 million and
requires 15 years. Moreover, they estimate that 90% of the average cost is secondary to the
regulatory delays. See Julie C. Relihan, Expediting FDA Approval ofAIDS Drugs: An International
Approach, 13 B.U. Int'l L.L 229,237 (1995).
186. Elizabeth M. Rutherford, The FDA and "Privatization"--The Drug Approval Process, 50
Food & Drug L.J. 203, 212 (1995); Tanya E. Karwaki, Comment, The FDA and the Biotechnology
Industry: A Symbiotic Relationship?, 71 Wash. L. Rev. 821, 828 (1996).
187. John Patrick Dillman, Prescription Drug Approval and Terminal Diseases: Desperate Times
Require Desperate Measures, 44 Vand. L. Rev. 925, 929 (1991); Relihan, supra note 185, at 237.
188. The United States, European Community nations, and Japan generate 90% of all
pharmaceutical research and constitute 75% of the market. Kanusky, supra note 177, at 667.
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profit. Therefore, drug development targets these populations and the
ailments that affect them. For example, in 1992, Parke-Davis, a large
U.S.-based pharmaceutical firm, planned to begin clinical trials for a new
anti-tuberculosis drug, sparfloxacin (a fluroquinolone), for which it held
limited U.S. development rights. However, these trials never got
underway because the world license holder, a Japanese company,
rescinded Parke-Davis' license, choosing to forego developing this drug
as a TB drug.'89 The owner was concerned that once sparfloxacin
obtained an TB indication, marketing the drug for other more prevalent
and profitable conditions like bronchitis and pneumonia' might be
harmed. 1' It feared that the drug would be stigmatized and less
marketable if its utility in treating TB was a primary treatment
indication. 9 2
By the late 1970s, it had become evident that the complex FDA
regimen was chilling new drug and vaccine development.'93 Unless a
drug was projected to be a clear "winner" in the market, the manufacturer
could not sustain the research and development costs plus the expense of
the lengthy approval process. In addition to much-delayed return on a
manufacturer's investment, the testing and approval process also
regularly consumed half or more of the period of patent protection.'
94
Although amendments in 1987 and 1994 alleviated this difficulty in part
by providing patent term extensions to offset delays,' 95 the manufacturers
argued that they still had inadequate time to recoup the ccsts of research
and development. As a result, manufacturers chose to develop only drugs
that would yield a higher profit margin. This meant that drugs targeted at
189. Reichman, supra note 8, at 175.
190. Such "profitable" conditions are suffered by a higher quotient of the adequately insured
populations of the world; the majority of tuberculosis patients, on the offier hand, are poor,
powerless, and uninsured.
191. Reichman, supra note 8, at 175.
192. Since then, WHO reportedly has receivw5 permission to study this drug for treatment of TB
in Europe. WHO continues to complain bitterly about the pharmaceutical industry's apparent
disinterest in developing new therapies to combat TB. Moreover, it argues that given the enormous
market for the current TB drugs, the prices could and should be lowered. WHO Accuses Industry of
Indifference to TB Dilemma, supra note 164.
193. See generally Kanusky, supra note 177; Christina Kent, Controver:ial FDA Overhaul
Advances in Congress, Am. Med. News, Apr. 22, 1996, at 3.
194. Until recently, the length of the patent term was 17 years. However, as of June 8, 1995, the
patent term length was increased to 20 years. See 35 U.S.C. § 154 (1996).
195. See 35 U.S.C. §§ 155-156 (1996) (detailing conditions pertaining to such extensions).
Despite the extensions, critics argue that they fail to adequately address the problems faced by
manufacturers. Jonathan L. Mezrich, The Patentability and Patent Term Extension of Lifesaving
Drugs: A Deadly Mistake, 6 J.L. & Health 111, 116-17 (1991-92).
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small or poor patient populations had little chance of getting off the
drawing board.'
Moreover, even if a manufacturer decided to forego the FDA process
in the United States in favor of the slightly less arduous processes of the
United Kingdom,197 other European countries,'98 and Japan,'99 there was
no reciprocity that would allow marketing in the lucrative U.S. market.2°°
Once the new drug or vaccine finally came to market, there was a
significant risk of product liability, particularly for vaccine
manufacturers. As a result of adverse events allegedly associated with
childhood immunizations, between 1980 and 1984 vaccine
manufacturers faced suits claiming up to $3.5 billion in damages.20 1
Several major manufacturers stopped making vaccines altogether.0 2
By the mid-1980s, childhood vaccines were in short supply and new
vaccine development was at a standstill.2 3 Drugs for rare but devastating
illnesses were not being developed. 2 4 As the effects of AIDS became
obvious, the inability of the pharmaceutical industry to deliver new drugs
in a timely fashion became a source of public consternation and
outrage.205 As a result, Congress acted to provide incentive programs to
196. Janice M. Hogan, Revamping the Orphan Drug Act: Potential Impact on the World
Pharmaceutical Market, 26 L. & Pol'y Int'l Bus. 523, 525-27 (1995). The length of the approval
process proved to be a barrier in responding to new disease challenges, as became glaringly evident
with the AIDS epidemic. In fact, a 1981 congressional survey revealed that 80% of drugs considered
"public service" drugs were the result of serendipitous discoveries, rather than from research targeted
to a specific disease. Peter S. Arno et al., Rare Diseases, Drug Development, andAIDS: The Impact
of the Orphan Drug Act, 73 Milbank Q. 231,233 (1995).
197. Veronica Henry, Problems with Pharmaceutical Regulation in the United States: Drug Lag
and Orphan Drugs, 14 J. Legal Med. 617, 637-39 (1993); Relihan, supra note 185, at 245-49.
198. See Kanusky, supra note 177, at 676-84.
199. See id. at 684-87. Although the perception is that foreign regulations are much less arduous
and time-consuming than the U.S. process, in reality the differences are slight. For example, a new
product in the United States typically takes 12 years to develop and costs $231 million to market
while a new product in a European Community nation takes 12-14 years to develop and costs $220
million to market. See id. at 682-83.
200. Indeed, even within the European Community, member states subject pharmaceutical
products to separate regulation. Id. at 680.
201. Randall B. Keiser, Deja Vu All Over Again? The National Childhood Vaccine Injury
Compensation Act of 1986, 47 Food & Drug L.J. 15, 16 (1992); see also Philip M. Boffey, Experts
Wfarn of'Precarious' Vaccine Supplies, N.Y. Times, July 30, 1985, at C10.
202. See Subcomm. on Health & the Env't of the House Comm. on Energy & Commerce, 99th
Cong., 2d Sess., Childhood Immunizations 86 (Comm. Print 1986).
203. Id. at 70-71.
204. See Carolyn H. Asbury, The Orphan Drug Act: The First 7 Years, 265 JAMA 893 (1991).
205. Ronald Podraza, The FDA's Response to AIDS: Paradigm Shift in New Drug Policy?, 48
Food & Drug L.J. 351, 352-54 (1993). There was widespread perception that the FDA attitude
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stimulate research and development of new treatment for certain diseases
and patient groups 6 -- incentives that might now be exploited or
modified to similarly stimulate research directed at the tuberculosis
epidemic.
V. EXPLOITING AND CREATING DRUG AND VACCINE
DEVELOPMENT INCENTIVES
Although changing cultural consciousness and stimulating sympathy
and interest in TB victims here and abroad is beyond the immediate
power of law and regulation, the law can and should be used to provide
regulatory, economic, and marketing incentives to the global
pharmaceutical industry to spur research and development of new drugs
and vaccines." 7 Indeed, we have already seen such incentives applied to
new treatments for AIDS in the form of a "fast track" regulatory process,
for drugs designed to treat so-called "orphan diseases," and to certain
vaccines. It also is possible that in the course of more fundamental, far-
reaching FDA reform, the regulatory climate might be dtered to favor
research and development of treatments for global epidemics.
A. Incentives Facilitating Development of New Drug Therapies
In response to demands by special-interest groups, Congress and the
FDA have provided pharmaceutical manufacturers with a series of
incentives to foster development of drugs and therapies for rare and
devastating diseases. Some of these incentives, such as the "fast track"
procedures applicable to new AIDS treatments, are designed to bring
new drugs to the market more quickly. Others like the "Orphan Drug
Act" stimulate the development of drugs and treatments that would not
be developed in the absence of such incentives. Both types of incentives
might be invoked and, if need be, reworked to facilitate research and
development of new tuberculosis drugs and vaccines.
1. Tuberculosis: An Orphan Under the Orphan Drug Act?
During the 1970s and 1980s, it became evident that new drugs for rare
diseases or diseases primarily affecting poor, uninsured populations were
towards AIDS and AIDS patients was "obstructionist, insensitive, inflexible aid otherwise cruelly
oblivious of their plight." Id.
206. See id. at 363.
207. See Reichman, supra note 8, at 175-77.
954
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not being developed.2" 8 Such diseases were tagged orphan diseases-
orphaned because no one sought to offer pharmaceutical treatments and
remedies for them. Such orphan diseases, while frequently tragic,
affected relatively few unfortunate victims.2" Developing a drug for an
orphan disease would not produce a profit for the increasingly profit-
driven pharmaceutical manufacturer.210
Congress acted to remedy this situation by passing the Orphan Drug
Act of 1983," through which pharmaceutical firms were provided with
three separate incentives to develop drugs for such orphan diseases. First,
Congress provided for tax credit-a credit, not just a deduction-of fifty
percent of the cost of the clinical trial during the time the designated
orphan drug is seeking approval." 2 Second, the Act provided for
additional government planning assistance to the company throughout
the course of the clinical trials and approval process.2"3 Finally and most
importantly, the Orphan Drug Act granted the pharmaceutical company
seven years of market exclusivity, regardless of whether or not the new
orphan drug was patentable.2"4
The benefits of the Orphan Drug Act were subject to certain limits,
however. First, only in very select situations will more than a single drug
be deemed an orphan drug for a given disease.21 In addition, the
incentives, especially the market exclusivity incentive, are only available
to a narrow class of prospective drugs. The orphan drug designation is
limited to drugs developed for diseases affecting less that 200,000
persons in the United States.2 16 The narrow classification was somewhat
broadened by a 1985 amendment to the Act, under which drugs for
diseases affecting more than 200,000 people in the United States qualify
for orphan drug status if there is no reasonable expectation that the costs
208. See supra notes 196-204 and accompanying text.
209. See Asbury, supra note 204, at 893; Donna Brown Grossman, The Orphan Drug Act:
Adoption or Foster Care?, 39 Food Drug Cosmetic L.L 128 (1984); Hogan, supra note 196, at 525.
210. See Henry, supra note 197, at 629.
211. 21 U.S.C. §§ 360aa-360ee (1994).
212. See 26 U.S.C. § 28(a) (1996). This tax credit was available only for expenses incurred
through the end of 1994. 26 U.S.C. § 28(e) (1996).
213. 21 U.S.C. § 360aa.
214. 21 U.S.C. § 360cc.
215. A second drug can be approved for the same indication when the first manufacturer is unable
to produce the drug in adequate quantities, when the second company obtains the consent of the first
to enter the market, when the first chooses to exit the market, or when the second newer orphan drug
is proven to be superior to the initial drug for the treatment indications. Hogan, supra note 196, at
529.
216. 21 U.S.C. § 360bb(a)(2).
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of development and manufacturing can be recouped from U.S. sales.217
Moreover, the market exclusivity provision remains applicable even if
the target population grows during the period of exclusivity to greater
than 200,000.218
Passage of the Orphan Drug Act had an almost immediate effect upon
drug development for orphan diseases, such as cystic fibrosis"' and
Gaucher's disease." 0 Although only ten drugs treating such orphan
diseases had traversed the FDA regulatory maze to approval in the
decade preceding the Orphan Drug Act, eighty-seven new drugs were
brought to market in the first decade after implementation of the Orphan
Drug Act.221 Clearly the Orphan Drug Act has achieved its purpose of
facilitating new drug development for rare, frequenily devastating
diseases.
However, the Act has had some unintended consequences that tarnish
its image. Many pharmaceutical companies have managed to extract
windfall profits by high pricing despite the small numbers of orphan
disease patients targeted. For example, Genentech's human growth
hormone, an orphan drug that treats a pituitary deficiency,222 earned $580
million during its first five years of exclusive marketing, thus recovering
over ten times the forty-five million dollars of research ard development
costs.2" A single year's supply of the orphan drug Ceredase, used to treat
Gaucher's disease, costs $350,000.24 These astronomical costs generally
are paid by the health plan-assuming of course that the patient is lucky
217. 21 U.S.C. § 360bb(a)(2).
218. 21 U.S.C. § 360ee.
219. Cystic fibrosis is a hereditary disorder characterized by pancreatic dysFunction and chronic
progressive respiratory disease; patients frequently succumb as young adults.
220. This hereditary enzyme deficiency presents in several different forms, ranging from a
devastating infantile form to a milder adult form. The adult form of the disease is characterized by
disorders of blood and clotting, pulmonary disease, and liver dysfunction; more severe forms of the
disease impair the neurologic system. Care and treatment of patients with Gaucher's disease has
changed materially with the development of a replacement enzyme, marketed as Ceredase, which
was developed as an orphan drug.
221. Hogan, supra note 196, at 530; see also Arno et al., supra note 196, at 2:12.
222. Patients with this type of deficiency have a dysfunction of the pituitary gland, a small gland
in the brain. The pituitary is responsible for triggering the release of a variety of hormone necessary
for normal life, including reproductive hormones, thyroid hormones, and growti hormone. The latter
is responsible for normal growth; if it is lacking, it must be supplemented to assure normal height
and maintain certain other metabolic parameters within normal range.
223. Hogan, supra note 196, at 530.
224. Id. at 531.
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enough to qualify for insurance or a liberal Medicaid plan.2" In addition,
pharmaceutical companies have learned to divide a more common
disease into discrete, narrow subdivided disease entities or indications to
qualify for the orphan drug designation; this practice is referred to as
"slicing the salami" by industry pundits.226  Alternatively, a
pharmaceutical company may ostensibly seek orphan drug status for a
new drug to treat a rare hormone disorder, even while realizing the drug
will have great utility in treating a common malady like infertility.227
Upon reaching the market, physicians and patients are made aware of the
orphan drug's versatility, and physicians simply prescribe the drug "off-
label" for the more common condition. 8 Several legislative attempts to
ameliorate these problems have been unsuccessful. 9
The Orphan Drug Act and its unintended loopholes may well provide
the most fertile ground for facilitating the development of new TB drugs.
Only a tiny percentage of the world's tuberculosis is found in the United
States. In fact, despite 100 million patients infected with MDR-TB
worldwide, and predictions for thirty million deaths in the next decade,
there were only 22,812 cases of active tuberculosis reported in the United
States in 1995,"O well under the 200,000 threshold for orphan disease
designation. In addition, it might well be possible to gain a second
orphan drug designation for a drug dedicated to MDR-TB, and
potentially a third designation for a drug targeting the combination
disorder TB and HIV. Such "slicing of the salami" remains possible
225. Use of insurance health plans and Medicaid plans for coverage of such expensive drugs has
far-reaching implications. If the patient is a member of a small health plan the cost of the premium
for the coverage may increase dramatically as the small group's subscribers offset the cost of this
extreme expense. See id. at 531-32. Similarly if the patient is covered under a state Medicaid plan,
this single patient may use so many financial resources that many other worthy Medicaid patients are
foreclosed from eligibility.
226. Id at 533; see also Amo et al., supra note 196, at 237.
227. For example, a new drug, D-Nase, developed by Genentech for cystic fibrosis (CF) may have
orphan status on the basis of its use for CF, but it also may be effective against more common
afflictions, like bronchitis and pneumonia-afflictions likely to be widespread in developed nations.
See Hogan, supra note 196, at 533.
228. See id.; Amo et al., supra note 196, at 240. "Off-label" use means that the drug is used for an
indication not authorized by the descriptive label approved by the FDA. For a more in depth
discussion of off-label use of drugs and the scientific, ethical, and economic implications of this
practice, see Richard M. Cooper, Unapproved Uses of Drugs: An Analysis and Some Proposals, 49
Food & Drug L.J 533 (1994).
229. See Hogan, supra note 196, at 535-36.
230. TB's Resurgence Calls for New Drugs, supra note 151. Note, however, that these promising
statistics are not found elsewhere in the world, particularly in the developing world where 97% of
tuberculosis occurs. This will make continued success of public health efforts in industrialized
nations ever more susceptible to erosion.
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under the Act as currently implemented. Moreover, assuming the best-
case scenario in which three manufacturers could develop orphan drugs
for each of the these three indications, each might benefit from market
exclusivity and also exploit more general utility-and profit-from the
new drugs through wide "off-label" use. Although Congress and the
FDA do not condone this practice, neither have they prohibited it.
With respect to global use of the drugs, the pharmaceutical industry
will not find complementary Orphan Drug Acts in other countries. In
fact, no other countries have implemented such incentives.u As a result,
the global community gets a free ride to orphan drugs3 2 In the case of
drugs applicable to diseases that are global orphans-that is, diseases
that are rare throughout the world-manufacturers frequently shift the
cost to U.S. consumers because pricing of drugs is stringently controlled
in other industrialized nations, the majority of which have nationally
regulated universal healthcare systems.33 This, of course, markedly
increases the price of the orphan drug for U.S. consumers, who purchase
at a market price that covers the manufacturer's costs plus whatever
profit the market will bear. 4 However, in the postulated case scenario
for new TB drugs, this cost shifting will be minimized by virtue of the
large global volume of patients. Thus, although pharmaceutical
companies might not, in the United States, make a "windC-all" profit like
that enjoyed by Genentech,s a healthy profit could easily be achieved
without massive cost-shifting, given the enormous incidence of
tuberculosis worldwide. 36
2. Expediting FDA Approvals: Jumping onto the "Fast Track"
Pharmaceutical manufacturers who developed new TB drugs targeting
MDR-TB and TB/HIV patients might also avail themselves of one or
231. Hogan, supra note 196, at 537.
232. Id. at 537-38.
233. See International Prescription Drug Prices: Hearing Before the Subcomm. on Health and
the Env't of House Comm. on Energy and Commerce, 103d Cong., Ist Sess. (1993).
234. Hogan, supra note 196, at 548.
235. See supra notes 220-232 and accompanying text.
236. The cost of a typical orphan drug can be shared among only a finite number of patients
around the world. Cost sharing is further permuted by the fact that many countrirs limit the price that
can be charged for pharmaceutical products in their countries. As a result, the co:;t-shifting burden on
the U.S. patient is multiplied. Unlike most orphan drugs that are dedicated to rare orphan diseases
afflicting a small number of patients new TB dr.gs would treat disease, that, although relatively rare
in the United States, is rampant elsewhere in the world. Thus, given the great volume of patients, the
cost shifting burden is unlikely to be as severely disproportionate, and may even be negligible.
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more of the expedited FDA processes originally provided to stimulate
development and dissemination of new AIDS therapies. These "fast
track" and early-access provisions inaugurated a new era in drug
regulation in the United States. For the first time, disease severity and
urgency of market need became factors in the FDA review and approval
process. 7 As such, they somewhat alter the long-standing primacy of
incontrovertible proof of "safety and efficacy" as the sole standard for
FDA approval and marketing."
One category of provisions provides patients with early access to
drugs and therapies that are still in the research pipeline. These
provisions include the "treatment use of an investigational new drug"
("Treatment IND") program 9 and the parallel track program.24 Use of
the latter program is limited to drugs dedicated to HIV,241 but with the
strong association between HIV and TB, new drugs targeting TB should
be able to use the parallel track program. However, neither of the two
early access programs are likely to be useful in developing and
disseminating new drugs to masses of patients, as would be necessary in
the case of tuberculosis. Both are designed to deliver drugs to a small,
carefully followed population of patients.
Of greater promise with respect to fostering new drugs for TB are the
so-called "fast track" provisions. Two major fast track options are
currently available to pharmaceutical manufacturers and could be utilized
in conjunction with widespread distribution of new TB drugs.
The first of these, the "Subpart F" provisions,242 allow for
compression of the clinical investigation phase of drug review; the
237. Sheila P. Shulman & Jeffrey S. Brown, The Food and Drug Administration's Early Access
and Fast-Track Approval Initiatives: How Have They Worked?. 50 Food & Drug L. J. 503, 503
(1995).
238. See infra notes 179-187 and accompanying text.
239. See 21 C.F.R. § 312.34 (1996). The treatment IND program builds on several previous
access programs that allowed patients suffering from life-threatening or serious illness to have
"compassionate" access to new drugs that were not yet fully approved for marketing. See Frank E.
Young et al., The FDA's New Procedures for the Use of Investigational Drugs for Treatment, 259
JAMA 2267 (1988).
240. The parallel track process, announced at 57 Fed. Reg. 13,250 (1992), provides an
administrative process to expand availability of new drugs directed at HIV patients. Under the
parallel track, patients who would otherwise be unable to participate in clinical trials of promising
nev drugs are allowed access to the drugs. However, the attending physicians are required to file
reports and data with the FDA and there are several layers of oversight. See Shulman & Brown,
supra note 237, at 509-10.
241. 57 Fed. Reg. 13,250 (1992) ("This parallel track policy describes processes specifically for
AIDS and other H1V-related diseases.").
242. 21 C.F.RL § 312.80 (1996).
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amount of compression is tailored t0 the severity of the disease threat and
the availability of alternative treatments.243 Initiated in 19:38,244 this "fast
track" allows the FDA to provide a shortcut through the lengthy phase
111241 testing process for drugs aimed at patients suffering from life
threatening and seriously debilitating diseases.2 46 Tuberculosis easily
qualifies under this criteria. This expedited process was used to bring
AZT and several other drugs to market quickly to meet the critical needs
of HIV patients.247 Subpart E has succeeded in materially decreasing the
time required for FDA review. 8 In fact, a recent study eLetermined that
use of subpart E could shave 3.3 years off the total regulatory phase
required to bring a new drug to the market.249
Yet another "fast track" that pharmaceutical manufacturers could use
for anti-tuberculosis drugs is the new "surrogate marker" programY The
"surrogate marker" program requires the manufacturer to show that the
drug is effective with respect to a surrogate endpoint25' that can be
reasonably correlated to a clinical benefit for patients suffering from a
similar, but not identical, seriously debilitating disease or disorder.252
Under this 1993 program, approval is even more accelerated, but there
may be conditions attached that limit rapid dissemination of the new
therapy.25 This new program is still "finding its feet" in the FDA
243. Subpart E states:
The Food and Drug Administration (FDA) has determined that it is appropriate to exercise the
broadest flexibility in applying the statutory standards, while preserving apprnpriate guarantees
for safety and effectiveness. These procedures reflect the recognition that physicians and
patients are generally willing to accept greater risks or side effects from products that treat life-
threatening and severely-debilitating illnesses, than they would accept from products that treat
less serious illnesses. These procedures also reflect the recognition that the benefits of the drug
need to be evaluated in light of the severity of the disease being treated.
21 C.F.R. § 312.80 (1996)
244. 21 C.F.R. § 312.84 (1996).
245. See text accompanying notes 185-186.
246. This "fast track" also allows clinical study of new drugs without requiring there to be a
"placebo" control group. See Relihan, supra note 185, at 240.
247. See Shulman & Brown, supra note 237, at 511.
248. d at 517. For example, Flutamide, a drug used to treat prostate can,.er completed FDA
review in a record 3.7 months. Id at 525.
249. Id. at 513.
250. See 21 C.F.R. §§ 314.500, 601.40 (1996).
251. A surrogate endpoint is a desirable outcome demonstrated in the context of a similar, but not
identical set of clinical circumstances or patient r opulation. See 21 C.F.P. § 314.510 (1996).
252. See 21 C.F.P. §§ 314, 601 (1996).
253. See Shulman & Brown, supra note 237, at 515-16.
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panoply of regulations and programs and has been utilized only
marginally. 4
The fast track programs could and should be used to expedite FDA
review and approval processes, thereby decreasing the cost and time
required to develop and disseminate new anti-tuberculosis products. It is
also possible that development of new tuberculosis therapies might be
enhanced by extending protection against liability to the pharmaceutical
companies. As discussed below, this method was successfully utilized to
stimulate the production of childhood vaccines.
B. Liability Protection: Building on the Past to Stimulate Vaccine and
Drug Development
More than drug manufacturers, vaccine manufacturers have
experienced the harsh reality of legal action for harms resulting from
allegedly defective or contaminated treatments. 5 Injured parties can
bring claims against manufacturer primarily on two theories:
negligence-that is, that the manufacturer breaches its duty, causing
harm to the patient; and strict liability-in which the patient will recover
damages because the product is defective, regardless of the conduct or
"fault" of the manufacturer.256 In strict liability, the theory is that a
manufacturer should have greater monetary exposure because it is in the
best position to provide for and insure against defective products.257 This
strict liability approach is limited however, when the product is
"unavoidably unsafe" as is the case with many vaccines.5 8
Despite the fact that many injuries resulting from vaccines are the
result of their "unavoidably unsafe" nature,259 vaccine manufacturers
have experienced heavy losses, both in the monetary and public relations
sense.26 A number of high profile suits in the 1960s and 1970s alleged
254. See id. at 516.
255. See H.R Rep. No. 99-908, at 4 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6347-48;
supra notes 201-203 and accompanying text.
256. NV. Page Keeton et al., Prosser andKeeton on the Law of Torts § 96, at 688 (5th ed. 1984).
257. Id § 98, at 692-94.
258. Id. § 99, at 701-02.
259. See supra notes 201-203 and accompanying text, see also Subcomm. on Health & the Env't
of the House Comm. on Energy & Commerce, 99th Cong. 2d Sess., Childhood Immunizations 21-33
(Comm. Print 1986).
260. See Vaccine Injury Compensation, 1984: Hearings on HR. 556 before the Subcomm. on
Health and the Environment of the House Comm. on Energy and Commerce, 98th Cong., 2d Sess.
295 (1984) (statement of Dr. Daniel Shaw, Jr. Vice President, Wyeth Laboratories).
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injury resulting from both oral polio vaccine and children's DPT
261vaccine.
In 1976, with the nation expecting an epidemic of swine flu and
vaccine manufacturers reluctant to produce a vaccine because of liability
fears, Congress acted swiftly and boldly to assuage their fears and
facilitate delivery of a vaccine.262
1. Government Assumption of Liability: Lessons Learnedfrom the
Swine Flu Vaccine Program
In response to the swine flu scare, Congress quickly enacted an
amendment to the Federal Tort Claims Act 63 that allowed victims
injured by the new vaccine to seek recovery from the federal
government.2" Under this scheme, the federal government, rather than
the manufacturer, would be the party compensating victims. The federal
government could go back to the manufacturer secondarily if the claim
was based on negligence-that is, where the manafacturer had
committed a breach of its duty of care in the manufacturing process-but
the plaintiff-friendly strict liability claims for a defective product would
be effectively covered by the federal government pursuant to the Federal
Tort Claims Act.265
Vaccine manufacturers rapidly developed and manufactured the new
swine flu vaccine. Forty million people in the United States were
immunized.26 6 Unfortunately, the vaccine had an untoward side effect; a
minority of patients developed Guillain-Barre Syndrome, a dangerous
261. See, e.g., Givens v. Lederle Lab., 556 F.2d 1341 (5th Cir. 1977); Reyes v. Wyeth Lab., 49S
F.2d 1264 (5th Cir.), cert. denied, 419 U.S. 1096 (1974); Davis v. Wyeth Lab. Inc., 399 F.2d 121
(9th Cir. 1968).
262. See Thomas E. Baynes, Jr., Liability for Vaccine Related Injuries: Public Health
Considerations and Some Reflections on the Swine Flu Experience, 21 St. Loui; U. L.J. 44, 64-66
(1977). This congressional action was further spured by the Legionnaire's Disese mini-epidemic in
Philadelphia during that congressional session. Although swine flu is remembered as only a minor
footnote today, in 1976 there was concern that it might rival a similar earlier flu that had taken 20
million lives worldwide. See H. William Smith, In, Vaccinating AIDS Vaccine Manufacturers
against Product Liability, 42 Case W. Res. L. Rev. 207, 219 (1992). See generally Richard E.
Neustadt & Harvey V. Fineberg, The Epidemic That Never Was: Policy Making and the Swine Flu
Affair (1983).
263. 28 U.S.C. §§ 2671-2678 (1994).
264. Arnold W. Reitze, Jr., Federal Compensation for Vaccination Induced Injuries, 13 B.C.
Envtl. Aff. L. Rev. 169, 178-79 (1986).
265. See Baynes, supra note 262, at 68.
266. Smith, supra note 262, at 221. The swine flu epidemic did not fully materialize.
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paralysis sometimes causing death and permanent disability.267 By 1985,
the cost of settlements and suit judgments was approaching $100 million,
far exceeding the budget allotted for the program.
2 61
Congress learned some valuable lessons from the swine flu episode-
lessons that it applied a few years later when it enacted the National
Childhood Vaccine Injury Act. The federal government would not again
assume liability with such naivet6.
2. Creation of a No-Fault Compensation System: The National
Childhood Vaccine Act Model
As noted above,269 manufacturers of children's vaccines began to feel
the bite of liability in the 1960s. In fact, some manufacturers began to
curtail their exposure as early as 1967 by getting out of the vaccine
270production business. It was not until the early 1980s, however, that
supplies of childhood vaccines became dangerously low, not only
globally but also in the United States.27
Once again, Congress acted to relieve manufacturers of some of their
liability concerns. In 1986, it enacted the National Childhood Vaccine
Injury Act,272 which put in place what is, in effect, a no-fault insurance
system for vaccine injuries sustained from compulsory childhood
vaccines. The program is funded by a excise tax on the vaccines.273
Patients sustaining a vaccine-related injury are eligible for compensation
under a defined injury-based compensation schedule that provides for
costs of medical and rehabilitative care, lost earnings, pain and suffering
and death benefits. 4 Once the patient takes advantage of the no-fault
compensation, they are foreclosed from taking their claim to court.27
267. See Reitze, supra note 264, at 181-82.
268. Smith, supra note 262, at 219. By the mid-1980s, the cost of claims was at $83 million and
rising. Reitze, supra note 264, at 185.
269. See supra notes 260-263 and accompanying text.
270. See supra notes 259-260 and accompanying text.
271. Daniel A. Cantor, Striking a Balance between Product Availability and Product Safety:
Lessons From the VaccineAct, 44 Am. U. L. Rev. 1853, 1959 (1995); Keiser, supra note 201, at 16.
272. Pub. L. No. 99-660, 100 Stat. 3755 (codified at 42 U.S.C. §§ 300aa-2 to 6, 10 to 17, 19, 21,
23, 25 to 28, 31 to 33 (1994)).
273. 26 U.S.C. §§ 4131-4132 (1994).
274. See 42 U.S.C. §§ 300aa-11 to 16 (describing the filing process and requirements, vaccine
injury tables, and compensation provisions and requirements).
275. 42 U.S.C. § 300aa-21.
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This no-fault program has been well received; by 1990, $56.8 million
had been disbursed to claimants. Moreover, legal and attorney costs were
minuscule-only three percent. There is also some evidence that the
program stabilized the vaccine market and prices. 6
A provision similar to the National Childhood Vaccine Injury Act
could provide incentives to potential manufacturers of new TB vaccines.
Like childhood vaccines, a TB vaccine would have wide use throughout
the world, and therefore would generate sales sufficient to compensate
for research and development costs. The fact that the vast majority of
vaccine would be used in poor, developing nations unable to pay high
prices and in nations with tightly regulated drug pricing systems would
be offset by the much diminished risk of liability costs in the United
States.
It is also possible that limitation of liability, its attendant costs, and its
effects on pharmaceutical development of drugs and vaccine for global
public health threats might be addressed in the context of more
fundamental reform of the cumbersome FDA regulatory scheme.
C. Revamping the Regulatory Regimen: FDA Reform
Many of those in the pharmaceutical industry as well as concerned
consumer groups believe that fundamental FDA reform is necessary to
decrease the costs and delays of the FDA process.277 As a result, we now
stand on the threshold of more formidable FDA reform, perhaps even
reform that radically changes the underlying FDA regulatory regimen.278
The more likely possibility, however, is that some level of incremental
reform will be made in the foreseeable future.
One de minimus reform might include some contracting out of FDA
regulatory review to private firms in order to decrease the cost and time
required for review and approval. In the case of more far-reaching reform
of the same ilk, the move toward privatization of FDA functions might
276. Smith, supra note 262, at 227-28. California subsequently enacted a similar statute targeting
development of AIDS vaccines. The California satute included no-fault provisions, but the patient
was not foreclosed from seeking recovery from the manufacturer as well, although no "double
dipping" was allowed. Id. at 229-30. This provition was short-lived and appears not to have been
implemented in any substantive way prior to its repeal in 1995.
277. See generally Dillman, supra note 187.
278. See Charles Marwick, Congress Moving to Improve FDA Performance, 275 JAMA 670
(1996). There is, of course, no guarantee that FDA reform will improve upon the system; radical
reform might so shake up the FDA regulatory bureaucracy that drug approval could be subject to
even more delay and confusion.
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be more profound.279 For example, the government might choose to
divest itself of the FDA, selling it or leasing it to private enterprise.2 0
Although it is unclear how such "privatization" would affect
development of drugs for the TB epidemic, it is likely that this reform
would not provide greater impetus to develop anti-tuberculosis drugs and
vaccines.
FDA reform might invoke greater, more general application of fast
tracks and expedited access provisions. Similarly, accentuated
enforcement mechanisms to force the FDA to comply with firm time
frames for each phase of the FDA process, and other streamlining
measures, have also been proposed.23' This type of reform would
facilitate the rapid dissemination of new drugs, including those aimed at
TB.
Yet another possibility is that Congress might take a page from the
Orphan Drug Act and provide tax incentives 282 and additional patent
protections to pharmaceutical manufacturers who develop drugs that
improve the global public health. Such incentive would promote the
development of not only anti-tuberculosis drugs, but also other needed
but less profitable drug therapies.
Additionally, it is possible that Congress might rewrite the Orphan
Drug Act. This might broaden the Act to target not only orphan drugs but
also public health focused drugs. Alternatively, Congress might act to
limit windfall profits, and thereby limit the unintended, but possibly
beneficial, loopholes available to companies developing new drugs. Such
a reform could therefore present a double-edged sword for new
tuberculosis drug development.
It is also possible, although somewhat unlikely, that Congress may
end to drugs or vaccines federal preemption of certain state law causes of
action that could be brought against the manufacturers. Although medical
device manufacturers enjoyed protection from liability under such a
preemption doctrine in the past, a recent U.S. Supreme Court case
279. See Rutherford, supra note 185, at 205-24.
280. See id. at 209-10.
281. See id. at 216. For an example of a recent bills proposing such measures, see Food and Drug
Administration Performance and Accountability Act of 1995, S. 1477, 104th Cong., 1st Sess. (1995)
and the Drug and Biological Products Reform Act of 1996, H.R. 3199, 104th Cong., 2nd Sess.
(1996).
282. For a detailed analysis of and proposal for such a reform, see Nina J. Crimm, A Tax Proposal
to Promote Pharmacologic Research, to Encourage Conventional Prescription Drug Innovation and
Improvement, and to Reduce Product Liability Claims 29 Wake Forest L. Rev. 1007 (1994).
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severely limited the scope of this preemptive protection. 83 As a result,
enactment of such a preemption is a remote possibility.
Perhaps the most fervent and popular proposed FDA refbrm is that the
United States at long last address the fact that the pharmaceutical market
is a global one. Although many decry the industry's apparent apathy with
respect to our reemerging tuberculosis epidemic, it cannot be denied that
drug and vaccine manufacturers answer to many masters in complying
with each nation's unique drug approval process.284 Much could be
achieved by harmonizing our drug approval system with that of other
industrialized nations.28 This would decrease research and development
costs by eliminating duplicative research trials, and would provide better
access to diverse populations for such trials.286 At the very least
harmonization would foster cooperation among nations and
pharmaceutical firms at a global level, providing a better base upon
which to develop new medications to treat and cure the global
tuberculosis epidemic.
V. CONCLUSION
Tuberculosis has returned to bedevil the world's population, and it has
returned in much more virulent forms. The public health strategies and
drugs that forced it into submission in the past are no match for the new
"white plague." Modernized public health techniques face
insurmountable barriers as a result of an obsolete and underfunded
infrastructure, due process constraints prohibiting enforced mandatory
treatment, and massive, virtually uncontrollable geographic mobility. All
of these factors guarantee ever greater spread of tuberculosis. If the
nations of the world and their public health efforts are to make any
appreciable headway in curbing this epidemic, they must have new, more
effective drugs and vaccine therapies that allow them to circumvent these
formidable barriers.
283. See Medtronic, Inc. v. Lohr, 116 S. Ct. 2240 (1996) (holding that clause in Medical Devices
Act preempting states from regulating safety and effectiveness of medical devices did not preempt
all state law causes of action brought by iniured patient against manufacturer of defective
pacemaker).
284. See Kanusky, supra note 177, at 688-95; Eric M. Katz, Europe's Cen.'ralized New Drug
Procedures: Is the United States Prepared to Keep Pace?, 48 Food & Drug L.J. 577 (1993).
285. There has already been some promising movement in this direction. For example, the recent
extension of the patent term from 17 to 20 year3 was largely for the purpose of harmonizing the
length of the term with that of other nations.
286. See Kanusky, supra note 177, at 703-06.
Vol. 71:919, 1996
Developing New TB Treatments
After a long period of stagnation, the pharmaceutical industry is
finally beginning to respond to public health pleas for new drugs to
combat TB. Finally there are early reports of promising new drug and
vaccine research.287 Nevertheless, such research and development faces a
harrowing maze of regulatory, financial, and market obstacles.
Regulation of the pharmaceutical industry should be restructured to
encourage these fledgling efforts by providing incentive programs to
overcome industry reluctance of developing new therapies for
tuberculosis before this epidemic extracts an even higher price in human
suffering and healthcare costs.
287. See, e.g., Daniel L DeNoon, Mycobacterial Antigen 85: Key to Effective TB Vaccine?,
Vaccine Wkly., Apr. 8, 1996, available in WESTLAW, 1996 WL 2001405; Licensing/Collaboration
Agreement on TB Vaccine Completed, Vaccine Wldy., Oct. 16, 1995, available in WESTLAW, 1995
WL 10121617; Warren Wilson, PathoGenesis' New TB Fighter Shows Promise, Seattle Post-
Intelligencer, Sept. 17, 1996, at B4.

